Altamira Therapeutics (CYTOF) 20-F 31 Mar 21 2020 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2020shares
Document Information Line Items
Entity Registrant Name	Auris Medical Holding Ltd.
Document Type	20-F
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding	12,869,587
Amendment Flag	false
Entity Central Index Key	0001601936
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Annual Report	true
Document Shell Company Report	false
Document Transition Report	false
Entity File Number	001-36582
Entity Incorporation, State or Country Code	D0
Entity Interactive Data Current	Yes

Consolidated Statement of Profi

Consolidated Statement of Profit or Loss and Other Comprehensive Income/(Loss)	12 Months Ended
	Dec. 31, 2020CHF (SFr)SFr / shares	Dec. 31, 2019CHF (SFr)SFr / shares	Dec. 31, 2018CHF (SFr)SFr / shares
Consolidated Statement of Profit or Loss and Other Comprehensive Income/(Loss) [Abstract]
Other operating income	SFr 174,475
Research and development	(2,862,979)	SFr (3,325,281)	SFr (6,689,589)
General and administrative	(2,594,662)	(3,933,863)	(4,264,534)
Operating loss	(5,283,166)	(7,259,144)	(10,954,123)
Interest income	258	17,882
Interest expense	(135,151)	(28,628)	(1,070,177)
Foreign currency exchange loss, net	(333,553)	(219,573)	(139,870)
Revaluation gain/(loss) from derivative financial instruments	(2,250,222)	663,725	1,350,071
Transaction costs	(219,615)		(520,125)
Loss before tax	(8,221,449)	(6,825,738)	(11,334,224)
Income tax gain/(loss)	21,284	193,837	(162,177)
Net loss attributable to owners of the Company	(8,200,165)	(6,631,901)	(11,496,401)
Items that will never be reclassified to profit or loss
Remeasurements of defined benefit liability, net of taxes of CHF 0	(26,118)	(72,010)	1,277,192
Items that are or may be reclassified to profit or loss
Foreign currency translation differences, net of taxes of CHF 0	88,862	16,446	(10,964)
Other comprehensive income/(loss), net of taxes of CHF 0	62,744	(55,564)	1,266,228
Total comprehensive loss attributable to owners of the Company	SFr (8,137,421)	SFr (6,687,465)	SFr (10,230,173)
Basic and diluted loss per share (in Francs per share) | (per share)	SFr (1.36)	SFr (2.28)	SFr (14.46)

Consolidated Statement of Pro_2

Consolidated Statement of Profit or Loss and Other Comprehensive Income/(Loss) (Parentheticals) - CHF (SFr)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Consolidated Statement of Profit or Loss and Other Comprehensive Income/(Loss) [Abstract]
Remeasurements of defined benefit liability, net of taxes	SFr 0	SFr 0	SFr 0
Foreign currency translation differences, tax	0	0	0
Other comprehensive income/(loss), net	SFr 0	SFr 0	SFr 0

Consolidated Statement of Finan

Consolidated Statement of Financial Position - CHF (SFr)	Dec. 31, 2020	Dec. 31, 2019
Non-current assets
Property and equipment	SFr 46,636	SFr 66,672
Intangible assets	9,115,410	6,765,613
Other non-current receivables	20,001	20,001
Total non-current assets	9,182,047	6,852,286
Current assets
Other receivables	80,861	335,299
Prepayments	277,589	434,231
Derivative financial instruments		219,615
Cash and cash equivalents	11,258,870	1,384,720
Total current assets	11,617,320	2,373,865
Total assets	20,799,367	9,226,151
Equity
Share capital	114,172	1,650,380
Share premium	177,230,300	157,191,707
Foreign currency translation reserve	61,297	(27,565)
Accumulated deficit	(160,635,879)	(152,778,389)
Total shareholders’ (deficit)/equity attributable to owners of the Company	16,769,890	6,036,133
Non-current liabilities
Derivative financial instruments	6,318	4,353
Employee benefit liability	867,376	760,447
Deferred tax liabilities	125,865	147,149
Total non-current liabilities	999,559	911,949
Current liabilities
Loan	523,920
Derivative financial instruments	310,439
Trade and other payables	762,453	938,247
Accrued expenses	1,433,106	1,339,822
Total current liabilities	3,029,918	2,278,069
Total liabilities	4,029,477	3,190,018
Total equity and liabilities	SFr 20,799,367	SFr 9,226,151

Consolidated Statement of Chang

Consolidated Statement of Changes in Equity	Share CapitalCHF (SFr)	Share PremiumCHF (SFr)	Foreign Currency Translation ReserveCHF (SFr)	Accumulated DeficitCHF (SFr)	CHF (SFr)	USD ($)
Balance at Dec. 31, 2017	SFr 19,349,556	SFr 114,648,228	SFr (33,047)	SFr (136,126,946)	SFr (2,162,209)
Total comprehensive loss
Net loss				(11,496,401)	(11,496,401)	$ (11,496,401)
Other comprehensive income / (loss)			(10,964)	1,277,192	1,266,228
Total comprehensive loss			(10,964)	(10,219,209)	(10,230,173)
Transactions with owners of the Company
Reorganization of group structure	(24,347,208)	24,347,208
Capital increase / Exercise of warrants	5,707,988	11,550,874			17,258,862
Transaction costs		(1,259,587)			(1,259,587)
Share based payments				42,757	42,757
Balance at Dec. 31, 2018	710,336	149,286,723	(44,011)	(146,303,398)	3,649,650
Total comprehensive loss
Net loss				(6,631,901)	(6,631,901)	(6,631,901)
Other comprehensive income / (loss)			16,446	(72,010)	(55,564)
Total comprehensive loss			16,446	(6,703,911)	(6,687,465)
Transactions with owners of the Company
Capital increase / Exercise of warrants	940,044	8,853,599			9,793,643
Transaction costs		(948,615)			(948,615)
Share based payments				228,920	228,920
Balance at Dec. 31, 2019	1,650,380	157,191,707	(27,565)	(152,778,389)	6,036,133
Total comprehensive loss
Net loss				(8,200,165)	(8,200,165)	$ (8,200,165)
Other comprehensive income / (loss)			88,862	(26,118)	62,744
Total comprehensive loss			88,862	(8,226,283)	(8,137,421)
Transactions with owners of the Company
Capital increase / Exercise of warrants	429,466	15,645,530			16,074,996
Transaction costs		(636,858)			(636,858)
Share based payments				368,793	368,793
Transactions with owners of the Company
Reduction par value	(1,973,044)	1,973,044
Conversion of loan	7,370	3,056,877			3,064,247
Balance at Dec. 31, 2020	SFr 114,172	SFr 177,230,300	SFr 61,297	SFr (160,635,879)	SFr 16,769,890

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - CHF (SFr)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities
Net loss	SFr (8,200,165)	SFr (6,631,901)	SFr (11,496,401)
Adjustments for:
Depreciation	20,036	30,823	72,713
Unrealized foreign currency exchange loss, net	10,818	21,290	211,214
Net interest expense	127,160	1,205	1,052,787
Loss on disposal of property and equipment			78,133
Share based payments	368,793	226,601	27,730
Transaction costs	219,615		520,125
Employee benefits	80,811	40,150	(37,491)
Revaluation loss/(gain) derivative financial instruments	2,250,222	(663,725)	(1,350,071)
Income tax loss/(gain)	(21,284)	(193,837)	162,177
Total	(5,143,994)	(7,169,394)	(10,759,084)
Changes in:
Other receivables	254,438	(18,925)	(18,390)
Prepayments	156,661	(82,948)	301,628
Trade and other payables	(175,878)	(898,088)	635,516
Accrued expenses	65,303	(224,077)	(3,391,834)
Net cash used in operating activities	(4,843,470)	(8,393,432)	(13,232,164)
Cash flows from investing activities
Purchase of property and equipment		(63,600)
Purchase of intangibles	(2,315,232)	(2,955,036)	(1,891,115)
Proceeds from disposals of property and equipment			68,160
Interest received	258	17,882
Net cash from / (used) in investing activities	(2,314,974)	(3,000,754)	(1,822,955)
Cash flows from financing activities
Proceeds from offerings and warrant exercises	16,074,996	9,793,643	17,447,499
Transaction costs	(636,858)	(948,615)	(2,006,577)
Proceeds from loans	1,522,931
Repayment of loan		(1,463,328)	(9,272,328)
Interest paid		(3,745)	(435,993)
Net cash from financing activities	16,961,069	7,377,955	5,732,601
Net increase / (decrease) in cash and cash equivalents	9,802,625	(4,016,231)	(9,322,518)
Cash and cash equivalents at beginning of the period	1,384,720	5,393,207	14,973,369
Net effect of currency translation on cash	71,525	7,744	(257,644)
Cash and cash equivalents at end of the period	SFr 11,258,870	SFr 1,384,720	SFr 5,393,207

Reporting entity

Reporting entity	12 Months Ended
	Dec. 31, 2020
Reporting entity [Abstract]
Reporting entity	Auris Medical Holding Ltd. (the “Company”) is an exempted company incorporated in Bermuda and is subject to Bermuda law. The Company’s registered address is Clarendon House, 2 Church Street, Hamilton HM11, Bermuda. These consolidated financial statements comprise the Company and its subsidiaries (together referred to as the “Group” and individually as “Group entities”). The Company is the ultimate parent of the following Group entities: ● Auris Medical AG, Basel, Switzerland (100%) with a nominal share capital of CHF 2,500,000 ● Otolanum AG, Zug, Switzerland (100%) with a nominal share capital of CHF 100,000 ● Zilentin AG, Zug, Switzerland (100%), with a nominal share capital of CHF 100,000 ● Altamira Medica AG, Zug, Switzerland (100%), with a nominal share capital of CHF 1,000,000 ● Auris Medical Inc., Chicago, United States (100%) with a nominal share capital of USD 15,000 ● Auris Medical Ltd., Dublin, Ireland (100%) with a nominal share capital of EUR 100 ● Auris Medical Pty Ltd, Collingwood, Australia (100%), with a nominal share capital of AUD 100 On April 22, 2014, the Company changed its name from Auris Medical AG to Auris Medical Holding AG. On May 21, 2014 the domicile of Auris Medical Holding AG was transferred from Basel to Zug. On March 13, 2018, the Company (“Auris OldCo”) merged (the “Merger”) into Auris Medical NewCo Holding AG (“Auris NewCo”), a newly incorporated, wholly-owned Swiss subsidiary following shareholder approval at an extraordinary general meeting of shareholders held on March 12, 2018. Following the Merger, Auris NewCo, the surviving company, had a share capital of CHF 122,347.76, divided into 6,117,388 (pre-2019 Reverse Share Split) common shares with a nominal value of CHF 0.02 (pre-2019 Reverse Share Split) each. Pursuant to the Merger, the Company’s shareholders received one common share with a nominal value of CHF 0.02 (pre-2019 Reverse Share Split) of Auris NewCo for every 10 of the Company’s common shares held prior to the Merger, effectively resulting in a “reverse stock split” at a ratio of 10-for-1. Auris NewCo changed its name to “Auris Medical Holding AG” following consummation of the Merger. Following shareholder approval at an extraordinary general meeting of shareholders held on March 8, 2019 and upon the issuance of a certificate of continuance by the Registrar of Companies in Bermuda on March 18, 2019, the Company discontinued as a Swiss company and, pursuant to Article 163 of the Swiss Federal Act on Private International Law and pursuant to Section 132C of the Companies Act 1981 of Bermuda (the “Companies Act”), continued existence under the Companies Act as a Bermuda company with the name “Auris Medical Holding Ltd.” (the “Redomestication”). The common shares of Auris Medical Holding Ltd. trade on the Nasdaq Capital Market under the trading symbol “EARS.” The Company is primarily involved in the development of therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focusing on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase 1b). Through its affiliate Altamira Medica, the Company is developing a nasal spray for protection against airborne viruses and allergens (AM-301). In addition, it has two Phase 3 programs under development, subject to its ability to obtain non-dilutive funding or partnering: (i) Keyzilen ® ® On May 1, 2019, the Company effected a one-for-twenty reverse share split (the “2019 Reverse Share Split”) of the Company’s issued and outstanding as well as unissued common shares. Unless indicated or the context otherwise requires, all per share amounts and numbers of common shares in this report have been retrospectively adjusted for the 2019 Reverse Share Split.

Basis of preparation

Basis of preparation	12 Months Ended
	Dec. 31, 2020
Basis of preparation [Abstract]
Basis of preparation	2. Basis of preparation Statement of compliance These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”). These consolidated financial statements were approved by the Board of Directors of the Company on March 30, 2021. Basis of measurement The consolidated financial statements are prepared on the historical cost basis, except for the revaluation to fair value of certain financial liabilities. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services. The principal accounting policies adopted are set out below. In addition, for financial reporting purposes, fair value measurements are categorized into Level 1, 2 or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows: ● Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date ● Level 2 inputs are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly; and ● Level 3 inputs are unobservable inputs for the asset or liability. Functional and reporting currency These consolidated financial statements are presented in Swiss Francs (“CHF”), which is the Company’s functional (“functional currency”) and the Group’s reporting currency. Redomestication The Redomestication of the Company from Switzerland to Bermuda is a continuance of its business. Therefore, the consolidated financial statements present the operation of Auris Medical Holding AG for the time before the Redomestication and of Auris Medical Holding Ltd for the time following the Redomestication. 2019 Reverse Share Split The Company effected the 2019 Reverse Share Split of its common shares at a ratio of 1-for-20. No fractional common shares were issued as fractional common shares were settled in cash. Impacted amounts and share information included in the consolidated financial statements and notes thereto have been adjusted for the reverse share split as if such reverse share split occurred on the first day of the periods presented. Certain amounts in the notes to the consolidated financial statements may be slightly different than previously reported due to rounding of fractional shares as a result of the reverse share split. Use of estimates and judgments The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions of accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Information about judgments made in applying accounting policies that have the most significant effects on the amounts recognized in the consolidated financial statements are described below. Income taxes As disclosed in Note 20 the Group has significant tax losses in Switzerland. These tax losses represent potential value to the Group to the extent that the Group is able to create taxable profits in Switzerland prior to expiry of such losses. Tax losses may be used within 7 years from the year the losses arose. The Group also has tax losses in the United States which may be used within 20 years of the end of the year in which losses arose, or for a shorter time period in accordance with prevailing state law. Other than a tax asset in the amount of CHF 476,363 (31.12.2019: CHF 91,851), the Group has not recorded any deferred tax assets in relation to these tax losses. Deferred tax assets on tax losses were only considered to the extent that they offset taxable temporary differences within the same entity. The key factors which have influenced management in arriving at this evaluation are the fact that the business is still in a development phase and the Group has not yet a history of making profits. Should management’s assessment of the likelihood of future taxable profits change, a deferred tax asset will be recorded. Income tax gain reflects the reassessment of deferred tax assets and liabilities booked in the 2020 fiscal year. Development expenditures The project stage forms the basis for the decision as to whether costs incurred for the Group’s development projects can be capitalized. For AM-201, AM-301, AM-101 and AM-111 clinical development expenditures are not capitalized until the Group obtains regulatory approval (i.e. approval to commercially use the product), as this is considered to be essentially the first point in time where it becomes probable that future revenues can be generated. For the Group’s intranasal betahistine program for the treatment of vertigo (AM-125), however, the development is primarily focused on the delivery route and formulation and not the drug itself (already an approved generic) and aims to demonstrate higher bioavailability through intranasal delivery. Given the nature of the development approach and the fact that there is an existing market in which oral betahistine for the treatment of vertigo has been approved, direct development expenditures have been capitalized. In addition, the Group has capitalized certain milestone payments with regarding to license payments. As of each reporting date, the Group estimates the level of service performed by the vendors and the associated costs incurred for the services performed. As part of the process of preparing the Group’s financial statements, the Group is required to estimate its accrued expenses. This process involves reviewing contracts, identifying services that have been performed on the Group’s behalf and estimating the level of service performed and the associated cost incurred for the service when it has not yet been invoiced or otherwise notified of the actual cost. Employee benefits The Group maintains a pension plan for all employees in Switzerland through payments to a legally independent collective foundation. This pension plan qualifies under IFRS as defined benefit pension plan. The Group’s net obligation in respect of defined benefit plans is calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods, discounting that amount and deducting the fair value of any plan assets. The Company makes relevant actuarial assumptions with regard to the discount rate, future salary increases and life expectancy. Research and Development and Accrued Expenses The Company records the costs associated with research, nonclinical and clinical trials, and manufacturing process development as incurred. These costs are a significant component of the Company’s research and development expenses, with a substantial portion of the Company’s on-going research and development activities being conducted by third party service providers, including contract research and manufacturing organizations. The Company accrues for expenses resulting from obligations under agreements with contract research organizations (“CROs”), contract manufacturing organizations (“CMOs”), and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accrued expenses are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrued expense balance in each reporting period. In the event advance payments are made to a CRO, CMO, or outside service provider, the payments will be recorded as prepayments which will be expensed as the contracted services are performed. Inputs, such as the services performed, the number of patients enrolled, or the trial duration, may vary from the Company’s estimates. As actual costs become known, the Company adjusts its prepayments and accrued expenses.

Significant accounting policies

Significant accounting policies	12 Months Ended
	Dec. 31, 2020
Significant accounting policies [Abstract]
Significant accounting policies	3. Significant accounting policies The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements, unless otherwise indicated. Basis of consolidation Subsidiaries Subsidiaries are entities controlled by the Group. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. Transactions eliminated on consolidation All inter-company balances, transactions and unrealized gains on transactions have been eliminated in consolidation. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Segment reporting A segment is a distinguishable component of the Group that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Group’s other components. The Chief Executive Officer is determined to be the Group’s Chief Operating Decision Maker (“CODM”). The CODM assesses the performance and allocates the resources of the Group as a whole, as all of the Group’s activities are focusing on the development of therapeutics for the treatment and prevention of ear, nose, throat and related disorders. Financial information is only available for the Group as a whole. Therefore, management considers there is only one operating segment under the requirements of IFRS 8, Operating Segments. Foreign currency Foreign currency transactions Items included in the financial statements of Group entities are measured using the currency of the primary economic environment in which the entity operates. Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss. Non-monetary items that are measured based on historical cost in a foreign currency are not re-translated. Foreign operations Assets and liabilities of Group entities whose functional currency is other than CHF are included in the consolidation by translating the assets and liabilities into the reporting currency at the exchange rates applicable at the end of the reporting period. Income and expenses are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transaction). These foreign currency translation differences are recognized in Other Comprehensive Loss and presented in the foreign currency translation reserve in equity. When a foreign operation is disposed of such that control is lost, the cumulative amount in the translation reserve related to that foreign operation is reclassified to profit or loss as part of the gain or loss on disposal. Closing rates for the most significant foreign currencies relative to CHF: Currency Geographical area Reporting December 31, December 31, December 31, CHF Swiss Franc Switzerland 5 1.0000 1.0000 1.0000 USD Dollar United States 1 0.8840 0.9674 0.9827 EUR Euro Europe 1 1.0817 1.0855 1.1283 AUD Dollar Australia 1 0.6822 — — Average exchange rates for the year for the most significant foreign currencies relative to CHF: Currency Geographical area Reporting 2020 2019 2018 CHF Swiss Franc Switzerland 5 1.0000 1.0000 1.0000 USD Dollar United States 1 0.9581 0.9938 0.9768 EUR Euro Europe 1 1.0825 1.1128 1.1573 AUD Dollar Australia 1 0.6546 — — Property and equipment Property and equipment is measured at historical costs less accumulated depreciation and any accumulated impairment losses. Historical costs include expenditures that are directly attributable to the acquisition of the items. When parts of an item of tangible assets have different useful lives, they are accounted for as separate tangible asset items (major components). Depreciation is calculated on a straight-line basis over the expected useful life of the individual asset or the shorter remaining lease term for leasehold improvements. The applicable estimated useful lives are as follows: Production equipment 5 years Office furniture and electronic data processing equipment (“EDP”) 3 years Leasehold improvements 5 years Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognized. All other repairs and maintenance are charged to profit or loss during the financial period in which they are incurred. Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate. When an asset is reviewed for impairment, the asset’s carrying amount may be written down immediately to its recoverable amount, provided the asset’s carrying amount is greater than its estimated recoverable amount. Management assesses the recoverable amount by assessing the higher of its fair value less costs to sell or its value in use. Cost and accumulated depreciation related to assets retired or otherwise disposed are removed from the accounts at the time of retirement or disposal and any resulting gain or loss is included in profit or loss in the period of disposition. Intangible assets Research and development Expenditures on the Group’s research programs are not capitalized, they are expensed when incurred. Expenditures on the Group’s development programs are generally not capitalized except if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group intends to and has sufficient resources to complete development and to use or sell the asset. For the development projects of the Group, these criteria are generally only met when regulatory approval for commercialization is obtained. This has been the general assessment for AM-201, AM-301, AM-101, and AM-111. For the AM-125 program for the treatment of vertigo it is the Group’s assessment that the criteria mentioned above are met and therefore direct development expenditures have been capitalized for AM-125 in 2018, 2019 and 2020. Intellectual property-related costs for patents are part of the expenditure for research and development projects. Therefore, the costs for the prosecution and registration of patents are expensed when incurred as long as the research and development project concerned does not meet the criteria for capitalization. In case of AM-125, where in 2019 a US patent was issued and a related EU application was allowed, prosecution and registration costs have been capitalized as the criteria have been met. Licenses, intellectual property and data rights Intellectual property rights that are acquired by the Group are capitalized as intangible assets if they are controlled by the Group, are separately identifiable and are expected to generate future economic benefits, even if uncertainty exists as to whether the research and development will ultimately result in a marketable product. Consequently, upfront and milestone payments to third parties for the exclusive use of pharmaceutical compounds in specified areas of treatment are recognized as intangible assets. Measurement Intangible assets acquired that have finite useful lives are measured at cost less accumulated amortization and any accumulated impairment losses. Subsequent expenditure Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated goodwill and brands, is recognized in profit or loss as incurred. Amortization All licenses of the Group have finite lives. Amortization will commence once the Group’s intangible assets are available for use which will be the case after regulatory approvals are obtained and the related products are available for use. Amortization of licenses is calculated on a straight-line basis over the period of the expected benefit or until the license expires, whichever is shorter. The estimated useful life is 10 years or the remaining term of patent protection. The Group assesses at each statement of financial position date whether intangible assets which are not yet ready for use are impaired. Impairment of non-financial assets Property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units). An impairment loss is recognized as the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell or value in use. Impairment losses are recognized in profit or loss. Assets that were previously impaired are reviewed for possible reversal of the impairment at each reporting date. Any increase in the carrying amount of an asset will be based on the depreciated historical costs had the initial impairment not been recognized. Financial instruments The Group classifies its financial assets in the following categories: loans and receivables based on the expected loss model. The classification depends on the nature and purpose of the financial assets and is determined at the time of initial recognition. The date of initial application (i.e. the date on which the Company has assessed its existing financial assets and financial liabilities in terms of IFRS 9 requirements) is January 1, 2018. Accordingly, the Company has applied the requirements of IFRS 9 to instruments that continue to be recognized at January 1, 2018 whereas for the year ended December 31, 2017 IAS 39 was applied. Recognition and derecognition of non-derivative financial assets and liabilities The Group initially recognizes loans and receivables and debt securities issued on the date when they are originated. All other financial assets and financial liabilities are initially recognized on the trade date. The Group derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred, or it neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control over the transferred asset. Any interest in such derecognized financial assets that is created or retained by the Group is recognized as a separate asset or liability. The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled, or expired. Financial assets and financial liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Group has a legal right to offset the amounts and intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously. Non-derivative financial assets and liabilities—measurement Loans and receivable These are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Loans and receivables are initially recognized at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, they are measured at amortized cost using the effective interest method, less expected losses. Cash and cash equivalents The Group considers all short-term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to an insignificant risk of changes in value with original maturities of three months or less at the date of the purchase to be cash equivalents. Non-derivative financial liabilities—measurement Non-derivative financial liabilities are initially recognized at fair value less any directly attributable transaction costs. Subsequent to initial recognition, these liabilities are measured at amortized cost using the effective interest method. Convertible loans In a convertible loan classified as a hybrid contract containing a host and a separated embedded derivative, both classified as liability, the carrying amount of the host contract at initial recognition is the difference between the carrying amount of the hybrid contract and the fair value of the embedded derivative. Transaction costs that relate to the issue of the convertible loan are allocated to the host and embedded derivative in proportion to the allocation of the gross proceeds. Transaction costs relating to the embedded derivative are immediately recognized in profit and loss. Transaction costs relating to the host contract are included in the carrying amount of the liability. The host contract is then subsequently measured at amortized cost, using the effective interest method. Share capital All shares of the Company are registered shares and classified as part of shareholders’ equity. Incremental costs directly attributable to the issue of the Company’s shares, net of any tax effects, are recognized as a deduction from equity. The warrants are classified as a financial liability at fair value through profit or loss and the cost allocated to the liability component will be immediately expensed to the income statement. The Company has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future. Repurchase and reissue of ordinary shares (treasury shares) When shares recognized as equity are repurchased, the amount of the consideration paid, which includes directly attributable costs, net of any tax effects, is recognized as a deduction from equity. Repurchased shares are classified as treasury shares and are presented in the treasury share reserve. When treasury shares are sold or reissued subsequently, the amount received is recognized as an increase in equity and the resulting surplus or deficit (calculated as the difference between initial cost and fair value) on the transaction is presented within share premium. Impairment of non-derivative financial assets Financial assets are assessed at each reporting date to determine whether there is objective evidence of impairment. Objective evidence that financial assets are impaired includes: ● default or delinquency by a debtor; ● indications that a debtor or issuer will enter bankruptcy; ● adverse changes in the payment status of borrowers or issuers; ● the disappearance of an active market for a security; or ● observable data indicating that there is measurable decrease in expected cash flows from a group of financial assets. Financial assets measured at amortized cost The Group considers evidence of impairment for these assets at an individual asset level. An impairment loss is calculated as the difference between an asset’s carrying amount and the present value of the estimated future cash flows discounted at the asset’s original effective interest rate. Losses are recognized in profit or loss and reflected in an allowance account. When the Group considers that there are no realistic prospects of recovery of the asset, the relevant amounts are written off. If the amount of impairment loss subsequently decreases and the decrease can be related objectively to an event occurring after the impairment was recognized, then the previously recognized impairment loss is reversed through profit or loss. Derivative Financial Instruments Derivative financial instruments (assets) are accounted as the cost to obtain the rights from a third party to issue shares under the purchase agreement and changes in fair value are shown as profit or loss. The fair value calculation of the derivative financial instrument (asset) is adjusted on the utilization of the asset based on total dollar amount of the purchase agreement. Derivative financial instruments (liabilities) are accounted at fair value and changes in fair value are shown as profit or loss. The fair value calculation of the derivative financial instruments is based on the Black-Scholes option pricing model. Assumptions are made for volatility and the risk free rate in order to estimate the fair value of the instrument. Transaction cost related to derivative financial instruments are recorded through profit and loss. Embedded Derivatives Derivatives may be embedded in another contractual arrangement. The Group accounts for an embedded derivative separately from the host contract when: - The host contract is not an asset in the scope of IFRS 9 - The host contract is not itself carried at fair value through profit and loss (FVPL) - The terms of the Embedded Derivative would meet the definition of a derivative if they were contained in a separate contract - The economic characteristics and risks of the embedded derivative are not closely related to the economic characteristics and risks of the host The separated embedded derivatives were measured at fair value by an independent consultant applying a simulation –based valuation approach. Assumptions are made for volatility, risk free rate and other features of the instrument. All changes in the fair value of embedded derivatives were recognized in profit and loss. Income tax Income tax expense comprises current and deferred tax. It is recognized in profit or loss except to the extent that it relates to a business combination, or items recognized directly in equity or in Other Comprehensive Income. Current tax Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to tax payable or receivable in respect of previous years. It is measured using tax rates enacted or substantively enacted at the reporting date. Deferred tax Deferred income tax is recognized, using the balance sheet liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred tax is not recognized for: ● temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss; ● temporary differences related to investments in subsidiaries to the extent that the Group is able to control the timing of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future; and ● taxable temporary differences arising on the initial recognition of goodwill. Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off tax assets against tax liabilities and when they relate to income taxes levied by the same taxation authority and the Group intends to settle its tax assets and liabilities on a net basis. Employee benefits The Group maintains a pension plan for all employees in Switzerland through payments to a legally independent collective foundation. This pension plan qualifies under IFRS as defined benefit pension plan. There are no pension plans for the subsidiaries in Ireland, Australia and the United States. The Group’s net obligation in respect of defined benefit plans is calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods, discounting that amount and deducting the fair value of any plan assets. The recognized asset is limited to the present value of economic benefits available in the form of any future refunds from the plan or reductions in future contributions to the plan. In order to calculate the present value of economic benefits, consideration is given to any minimum funding requirements. Remeasurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognized immediately in Other Comprehensive Income. Past service costs, including curtailment gains or losses, are recognized immediately in general and administrative expenses within the operating results. Settlement gains or losses are recognized in general and administrative expenses within the operating results. The Group determines the net interest expense (income) on the net defined benefit liability (asset) for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period or in case of any significant events between measurement dates to the then-net defined benefit liability (asset), taking into account any changes in the net defined benefit liability (asset) during the period as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognized in profit or loss. Share-based compensation The Company maintains a share-based payment plan in the form of a stock option plan for its employees, members of the Board of Directors as well as key service providers. Stock options are granted at the Board’s discretion without any contractual or recurring obligations. The share-based compensation plans qualify as equity settled plans. The grant-date fair value of share-based payment awards granted to employees is recognized as an expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards. Under the Auris Medical Holding Ltd. Long Term Equity Incentive Plan (the “Equity Incentive Plan” or “EIP”), 50% of granted share options granted to employees vest after a period of service of two years from the grant date and the remaining 50% vest after a period of service of three years from the grant date. Share options granted to members of the Board of Directors granted from 2016 onwards vest after a period of one year after the grant date. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that meet the related service and non-market performance conditions at the vesting date. Share-based payments that are not subject to any further conditions are expensed immediately at grant date. In the year the options are exercised the proceeds received net of any directly attributable transaction costs are credited to share capital (par value) and share premium. Valuation of share options Option pricing and values are determined based on the Black Scholes option pricing model and assumptions are made for inputs such as volatility of the Company’s stock and the risk free rate. Provisions Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, where it is more likely than not that an outflow of resources will be required to settle the obligation, and where a reliable estimate can be made of the amount of the obligation. Provisions are not recognized for future operating losses. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. Earnings/(loss) per share Basic earnings/(loss) per share are calculated by dividing the net profit/(loss) attributable to owners of the Company by the weighted average number of shares outstanding during the period. Diluted earnings/(loss) per share are calculated by dividing the net profit/(loss) attributable to the owners of the Company by the weighted average number of shares outstanding during the period adjusted for the conversion of all dilutive potential ordinary shares.

New standards, amendments and i

New standards, amendments and interpretations adopted by the Group	12 Months Ended
	Dec. 31, 2020
Disclosure of expected impact of initial application of new standards or interpretations [text block] [Abstract]
New standards, amendments and interpretations adopted by the Group	4. New standards, amendments and interpretations adopted by the Group In 2020, the following revised standards have been adopted: IFRS 3 Amendments to IFRS 3, Definition of a business IAS 1/IAS 8 Amendments to IAS 1 and IAS 8, Definition of material IFRS 9/IAS 39/IFRS 7 Amendments to IFRS 9, IAS 39 and IFRS7, Interest Rate Benchmark Reform – Phase 1 IFRS 16 COVID-19 Rent-related Concessions (Amendments to IFRS 16) Conceptual Framework Amendments to References to the Conceptual Framework (Various Standards) Adoption has not had a material impact on the amounts reported in these financial statements but may impact the accounting for future transactions and arrangements. A number of new standards, amendments to standards and interpretations are effective for annual periods beginning after January 1, 2021, and have not been applied in preparing these consolidated financial statements. Standard/Interpretation Impact Effective date Planned application by the Group New standards, interpretations or amendments IFRS 9/IAS 39/IFRS 7/IFRS 4/IFRS 16 Amendments to IFRS 9/IAS 39/IFRS 7/IFRS 4/IFRS 16, Interest Rate Benchmark Reform – Phase 2 1) January 1, 2021 FY 2021 IAS 16 Amendments to IAS 16, Proceeds before Intended Use 1) January 1,2022 FY 2022 IAS 37 Amendments to IAS 37, Onerous contracts – Costs of Fulfilling a Contract 1) January 1, 2022 FY 2022 IFRS 3 Amendments to IFRS 3, References to the Conceptual Framework 1) January 1, 2022 FY 2022 IFRS 1, IFRS 9, IFRS 16, IAS 41 Annual improvements to IFRS Standards 2018-2020 Cycle 1) January 1, 2022 FY 2022 IFRS 17 Insurance contracts 1) January 1, 2023 FY 2023 IAS 1 Amendments to IAS 1, Classification of Liabilities as Current or Non-current 1) January 1, 2023 FY 2023 1) No material impact on the Group is expected from these standards and amendments issued but not effective.

Financial instruments and risk

Financial instruments and risk management	12 Months Ended
	Dec. 31, 2020
Disclosure of financial risk management [text block] [Abstract]
Financial instruments and risk management	5. Financial instruments and risk management The following table shows the carrying amounts of financial assets and financial liabilities: December 31, December 31, Financial assets Cash and cash equivalents 11,258,870 1,384,720 Loans and receivables Other receivables 10,040 80,040 Total financial assets 11,268,910 1,464,760 Financial liabilities At amortized cost Trade and other payables 762,453 938,247 Accrued expenses 1,433,106 1,339,822 Loan 523,920 — At fair value through profit and loss Derivative financial instruments 316,757 4,353 Total financial liabilities 3,036,236 2,282,422 Fair values The carrying amount of cash and cash equivalents, other receivables, trade and other payables, accrued expenses and loan is a reasonable approximation of their fair value due to the short-term nature of these instruments. Financial risk factors The Group’s activities expose it to a variety of financial risks: market risk, credit risk, interest rate and liquidity risk. The Group’s overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Group’s financial performance. Management identifies, evaluates and controls financial risks. No financial derivatives have been used in 2020 and 2019 to hedge risk exposures. The Group invests its available cash in instruments with the main objectives of preserving principal, meeting liquidity needs and minimizing foreign exchange risks. The Group allocates its liquid assets to first tier Swiss or international banks. Liquidity risk The Group’s principal source of liquidity is its cash reserves which are mainly obtained through the issuance of new shares. The Group has succeeded in raising capital to fund its development activities to date and has raised funds that will allow it to meet short term development expenditures. The Company will require regular capital injections to continue its development work, which may be dependent on meeting development milestones, technical results and/or commercial success. Management monitors rolling forecasts of the Group’s liquidity requirements to ensure it has sufficient cash to meet operational needs. The ability of the Group to maintain adequate cash reserves to sustain its activities in the medium term is highly dependent on the Group’s ability to raise further funds. Consequently, the Group is exposed to continued liquidity risk. The table below analysis the remaining contractual maturities of financial liabilities, including estimated interest payments as of December 31, 2020 and 2019. The amounts disclosed in the table are the undiscounted cash flows: Carrying Less than Between 2 years Total December 31, 2020 Trade and other payables 762,453 762,453 — — 762,453 Accrued expenses 1,433,106 1,433,106 — — 1,433,106 Loan and borrowings 523,920 473,920 50,000 523,920 Derivative financial instruments 316,757 310,439 — 6,318 316,757 Total 3,036,236 2,979,918 50,000 6,318 3,036,236 Carrying Less than Between 2 years Total December 31, 2019 Trade and other payables 938,247 938,247 — — 938,247 Accrued expenses 1,339,822 1,339,822 — — 1,339,822 Loan and borrowings — — — — — Derivative financial instruments 4,353 — — 4,353 4,353 Total 2,282,422 2,278,069 — 4,353 2,282,422 Fair value measurement Fair values as at Fair Financial assets / liabilities December 31, December 31, value Valuation technique(s) and key input(s) Derivative financial liabilities – Warrants from public offerings Liability 6,318 Liability Level 2 Black-Scholes option pricing model The share price is determined by Company’s NASDAQ quoted-price. The strike price and maturity are defined by the contract. The volatility assumption is driven by Company’s historic quoted share price and the risk free rate is estimated based on observable yield curves at the end of each reporting period. Derivative financial liabilities – Embedded derivatives 310,439 — Level 3 Monte Carlo simulation model The valuation is based on input parameters classified as level 3. Input parameters include the historical volatility of AMHL shares, risk-free rate, expected remaining life, expected exercise date and share prices of AMHL at valuation dates. Derivative financial asset Asset Asset Level 3 The fair value is equal to the price paid to the counter party for obtaining the right under the purchase agreement. — 219,615 Subsequent, the fair value is adjusted proportionally for the part of the right consumed. For level 3 financial liability, the sensitivity analysis below represents the potential absolute change in fair value. The favorable and unfavorable effects on the result before taxes, resulting from using reasonably alternative assumptions for the valuation of the option component of the Convertible Loan (FiveT) has been calculated by recalibrating the modes using unobservable inputs based on an average volatility of 5%. Dec 31, 2020 Dec 31, 2019 Increase/Decrease Effect on result Increase/Decrease Effect on result Change in volatility +5% 2,770 - -5% -5,475 - Changes in liabilities arising from financing activities Non-cash changes 01.01.2020 Financing 1) Fair Other 2) 31.12.2020 Derivative financial instrument 4,353 — 219,315 93,089 316,757 Loans — 1,522,931 — (999,011 ) 523,920 Total 4,353 1,522,931 219,315 (905,922 ) 840,677 Non-cash changes 01.01.2019 Financing 1) Fair Other 2) 31.12.2019 Derivative financial instrument 675,328 — (663,725 ) (7,250 ) 4,353 Loans 1,435,400 (1,463,328 ) — 27,928 — Total 2,110,728 (1,463,328 ) (663,725 ) 20,678 4,353 1) The financing cash flows are from loan borrowings or loan repayments. 2) Other non-cash changes include recognition of derivative, partial conversion and amortization of convertible loan, accrued interest and Foreign Exchange-Difference. Credit risk Credit risk is managed on a Group basis. Credit risk arises from cash and cash equivalents and deposits with banks, as well as from other receivables. The Company’s policy is to invest funds in low risk investments including interest bearing deposits. Other receivables were current as of December 31, 2020 and December 31, 2019, not impaired and included only well-known counterparties. The Group has been holding cash and cash equivalents in the Group’s principal operating currencies (CHF, USD and EUR) with international banks of high credit rating. The Group’s maximum exposure to credit risk is represented by the carrying amount of each financial asset in the consolidated statement of financial position: December 31, December 31, Financial assets Cash and cash equivalents 11,258,870 1,384,720 Other receivables 10,040 80,040 Total 11,268,910 1,464,760 As of December 31, 2020 and December 31, 2019 other receivables consisted in a bank deposit for guaranteeing credit card liabilities. Market risk Currency risk The Group operates internationally and is exposed to foreign exchange risk arising from various exposures, primarily with respect to US Dollar and Euro. Foreign exchange risk arises from future commercial transactions, recognized assets and liabilities and net investments in foreign operations. The summary of quantitative data about the exposure of the Group’s financial assets and liabilities to currency risk was as follows: 2020 2019 in CHF USD EUR USD EUR Cash and cash equivalents 9,214,709 694,287 1,041,695 125,631 Other receivables 479 — 154,063 — Trade and other payables (75,712 ) (397,853 ) (51,527 ) (526,637 ) Accrued expenses (34,648 ) (569,400 ) (750,949 ) (175,826 ) Net statement of financial position exposure -asset/(liability) 9,104,828 (272,966 ) 393,282 (576,832 ) As of December 31, 2020, a 5% increase or decrease in the USD/CHF exchange rate with all other variables held constant would have resulted in a CHF 455,241 (2019: CHF 19,664) increase or decrease in the net result. Also, a 5% increase or decrease in the EUR/CHF exchange rate with all other variables held constant would have resulted in a CHF 13,648 (2019: CHF 28,841) increase or decrease in the net result. The Company has subsidiaries in the United States, Australia and Ireland, whose net assets are exposed to foreign currency translation risk. Due to the small size of the subsidiaries the translation risk is not significant. Capital risk management The Company and its subsidiaries are subject to capital maintenance requirements under local law in the country in which it operates. To ensure that statutory capital requirements are met, the Company monitors capital, at the entity level, on an interim basis as well as annually. From time to time the Company may take appropriate measures or propose capital increases to ensure the necessary capital remains intact.

Segment information

Segment information	12 Months Ended
	Dec. 31, 2020
Segment information [Abstract]
Segment information	6. Segment information Geographical information The Group’s non-current assets by the Company’s country of domicile were as follows: December 31, December 31, Switzerland 9,030,778 6,852,286 Australia 151,269 — Total 9,182,047 6,852,286 Non-current assets exclude financial instruments.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2020
Disclosure of property, plant and equipment [text block] [Abstract]
Property and equipment	7. Property and Equipment Production Office Total At cost As of January 1, 2019 289,888 233,706 523,594 Additions 63,600 — 63,600 Disposals — — — As of December 31, 2019 353,488 233,706 587,194 Additions — — — Disposals — — — As of December 31, 2020 353,488 233,706 587,194 Accumulated depreciation As of January 1, 2019 (270,408 ) (219,291 ) (489,699 ) Charge for the year (20,083 ) (10,740 ) (30,823 ) Disposals — — — As of December 31, 2019 (290,491 ) (230,031 ) (520,522 ) Charge for the year (16,481 ) (3,555 ) (20,036 ) Disposals — — — As of December 31, 2020 (306,972 ) (233,586 ) (540,558 ) Net book value As of December 31, 2019 62,997 3,675 66,672 As of December 31, 2020 46,516 120 46,636 As of December 31, 2020, and 2019 no items of property and equipment were pledged.

Intangible assets

Intangible assets	12 Months Ended
	Dec. 31, 2020
Intangible assets [Abstract]
Intangible assets	8. Intangible assets Licenses IP & Data rights Patents Internally Total At cost As of January 1, 2019 1,482,520 193,989 — 1,858,731 3,535,240 Additions — — 239,593 2,990,780 3,230,373 As of December 31, 2019 1,482,520 193,989 239,593 4,849,511 6,765,613 Exchange differences 6,120 6,120 Additions — — 177,623 2,166,054 2,343,677 As of December 31, 2020 1,482,520 193,989 417,216 7,021,685 9,115,410 Accumulated amortization and impairment losses As of December 31, 2019 — — — — — As of December 31, 2020 — — — — — Net book value As of December 31, 2019 1,482,520 193,989 239,593 4,849,511 6,765,613 As of December 31, 2020 1,482,520 193,989 417,216 7,021,685 9,115,410 Intangible assets comprise upfront and milestone payments related to licenses. In 2013 a milestone payment of CHF 1,125,000 related to the AM-111 program was recorded. Amortization will commence once the intangible assets are available for use, which will be the case after regulatory approvals are obtained and the related products are available for use. On February 2, 2017, the Company entered into an asset purchase agreement with Otifex Therapeutics Pty Ltd (“Otifex”), pursuant to which the Company agreed to purchase and Otifex has agreed to sell to the Company certain pre-clinical and clinical assets related to a formulation for the intranasal application of betahistine, which the Company refers to as AM-125, as well as intellectual property rights. The Otifex transaction closed in July 2017 and the Company recorded CHF 146,580 as intangibles related to this transaction. On December 6, 2018, in two related transactions, the Company acquired an Orphan Drug Designation for betahistine in the treatment of obesity associated with Prader-Willi syndrome (PWS). In a related transaction, on May 15, 2019, the Company acquired two U.S. Patents relating to the use of betahistine for the treatment of depression and attention-deficit / hyperactivity disorder (ADHD), respectively. The Company recorded CHF 47,409 as intangibles related to these transactions. In 2019, a US patent on AM-125 was issued and a related EU application was allowed. As a consequence, we started to capitalize prosecution and registration costs. In 2020, we capitalized CHF 177,623 (2019: CHF 239,593). Commencing with the business year 2018, the Company recorded intangibles related to direct development expenditure of its AM-125 program. The capitalized amount for the year ended December 31, 2020 was CHF 2,343,677 (2019: CHF 3,230,373). No amortization or impairment was recorded in 2020 and 2019.

Other receivables

Other receivables	12 Months Ended
	Dec. 31, 2020
Other receivables [Abstract]
Other receivables	9. Other receivables December 31, December 31, Advance payments to suppliers 479 — Value added tax receivable 38,337 26,438 Withholding tax receivable 6,087 24,113 Deposit credit cards 10,040 80,040 Other 25,918 204,708 Total other receivables 80,861 335,299 Other receivables were not considered impaired in the years under review.

Prepayments

Prepayments	12 Months Ended
	Dec. 31, 2020
Prepayments [Abstract]
Prepayments	10. Prepayments December 31, December 31, Advance payments to suppliers 5,020 40,461 Clinical projects and related activities 164,916 265,842 Insurance 104,590 114,016 Other 3,063 13,912 Total prepayments 277,589 434,231

Cash and cash equivalents

Cash and cash equivalents	12 Months Ended
	Dec. 31, 2020
Disclosure of cash and cash equivalents [text block] [Abstract]
Cash and cash equivalents	11. Cash and cash equivalents December 31, December 31, Cash in bank accounts 11,258,870 1,383,182 Cash on hand — 1,538 Total cash and cash equivalents 11,258,870 1,384,720

Capital and reserves

Capital and reserves	12 Months Ended
	Dec. 31, 2020
Capital and reserves [Abstract]
Capital and reserves	12. Capital and reserves Share capital The issued share capital of the Company at December 31 consisted of: December 31, December 31, Number CHF Number CHF Common shares with a par value of CHF 0.01 each 11,417,159 114,172 — — Common shares with a nominal value of CHF 0.40 — — 4,125,949 1,650,380 Total 11,417,159 114,172 4,125,949 1,650,380 Common Shares (Number) 2020 2019 As of January 1 4,125,949 1,775,839 Public offering — 2,161,280 Exercise of warrants 1,263,845 — LPC equity line 1,610,120 89,880 ATM program 1,628,827 98,950 Share-based payments (bonus) 51,418 — Conversion convertible loan 737,000 — Registered direct offering 2,000,000 — Total, as of December 31 11,417,159 4,125,949 On December 3, 2020, the Company entered into securities purchase agreements with several institutional investors for the purchase and sale of 2,000,000 common shares at an offering price of $4.00 per share, pursuant to a registered direct offering. The net proceeds of the offering were approximately $7.3 million. On December 1, 2020, a tranche of the convertible loan provided by FiveT (please refer to note 25) in the amount of CHF 895,455 was converted into 737,000 common shares at a conversion price of $1.35. On April 23, 2020, the Company entered into a purchase agreement and a Registration Rights Agreement with Lincoln Park Capital Fund, LLC (the “2020 Commitment Purchase Agreement”). Pursuant to the purchase agreement, LPC agreed to subscribe for up to USD 10,000,000 of our common shares over the 30-month term of the purchase agreement. In 2020, we issued 1,200,000 of our common shares to LPC for an aggregate amount of USD 1.1 million. The 2020 Commitment Purchase Agreement replaced the 2018 Commitment Purchase Agreement. Under the 2018 Commitment Purchase Agreement agreed to purchase common shares for up to $10,000,000 over the 30-month term of the Purchase Agreement. Prior to its termination we had issued 587,500 common shares for aggregate proceeds of $1.8 million to LPC under the LPC Purchase Agreement. The Purchase Agreement replaced the Purchase Agreement that we entered into with LPC on October 10, 2017 (the “2017 Commitment Purchase Agreement”), which was terminated as a result of the Merger. Under the 2017 Commitment Purchase Agreement, LPC agreed to subscribe for up to $13,500,000 of our common shares, and prior to its termination, we had issued an aggregate of 2,600,000 (pre-merger) common shares for aggregate proceeds of $1.8 million to LPC under the 2017 Commitment Purchase Agreement. On May 15, 2019, the Company completed a public offering of (i) 440,000 common shares with a par value of CHF 0.40 each, together with warrants to purchase 440,000 common shares, and (ii) 1,721,280 pre-funded warrants, with each pre-funded warrant exercisable for one common share, together with warrants to purchase 1,721,280 common shares, including 110,000 common shares and warrants to purchase 110,000 common shares sold pursuant to a partial exercise by the underwriters of the underwriters’ over-allotment option (the “May 2019 Registered Offering”). The exercise price for the pre-funded warrants was CHF 0.01 per common share and for the warrants CHF 4.34. The net proceeds to us from the May 2019 Registered Offering were approximately $7.7 million, after deducting underwriting discounts and other offering expenses payable by us. All pre-funded warrants were exercised in 2019. In December 2020, 1,263,845 warrants were exercised, leaving 897,435 warrants outstanding as of December 31, 2020. These remaining warrants were exercised in March 2021. On November 30, 2018, we entered into the A.G.P. Sales Agreement with A.G.P. Pursuant to the terms of the A.G.P. Sales Agreement, as amended on April 5, 2019, we may offer and sell our common shares, from time to time through A.G.P. by any method deemed to be an “at-the-market” offering as defined in Rule 415(a)(4) promulgated under the Securities Act. Pursuant to the A.G.P. Sales Agreement, we may sell common shares up to a maximum aggregate offering price of $25.0 million. In 2020, we sold 1,628,827 shares under the ATM. As of the date of this Annual Report, we have sold 1,758,618 of our common shares for an aggregate offering price of $3.2 million pursuant to the A.G.P. Sales Agreement. In 2019, we sold 98,954 shares for an aggregate offering price of $978,415. The related transaction costs of CHF 71,161 were charged to equity. On November 27, 2018 and December 11, 2018, the Company entered into purchase agreements with FiveT Capital AG, providing for the issuance and sale by us of an aggregate of 165,750 of its common shares for an aggregate purchase price of CHF 1.6 million in two separate registered direct offerings. On July 17, 2018 the Company completed a public offering of 897,435 common shares with a nominal value of CHF 0.40, Series A warrants each entitling its holder to purchase 0.35 of a common share for an aggregate of 314,102 common shares, and Series B warrants entitling its holder to purchase 0.25 of a common share for an aggregate of 224,358 common shares (the “July 2018 Registered Offering”). As of December 31, 2019, the exercise price for the Series A Warrants was CHF 7.80 per common share and the exercise price for the Series B Warrants was CHF 3.95 per common share (which exercise price was automatically adjusted due to the May 2019 Registered Offering). Since the July 2018 Registered Offering, certain Series A warrant holders exercised their warrant shares to purchase 145,226 common shares of the Company and certain Series B warrant holders exercised warrant shares to purchase 143,221 common shares. On June 30, 2020, the Series B warrants expired without further warrants being exercised. The net proceeds to the Company from the July 2018 Registered Offering were approximately CHF 6.2 million, after deducting underwriting discounts and other offering expenses payable by us. The Company had transaction costs amounting to CHF 851,692. The transaction costs were recorded as CHF 742,833 in equity for the issuance of common shares and CHF 108,809 to finance expense in the statement of profit or loss and comprehensive loss for the issuance of the warrants. On May 2, 2018 the compnay entered into a purchase agreement (the “2018 Commitment Purchase Agreement”) and a registration rights agreement (the “2018 Registration Rights Agreement”) with Lincoln Park Capital LLC (“LPC”). Pursuant to the 2018 Commitment Purchase Agreement, LPC agreed to purchase common shares for up to $10,000,000 over the 30-month term of the 2018 Commitment Purchase Agreement. As of the date of these consolidated financial statements, the Company has issued an aggregate of 89,880 common shares for aggregate proceeds of CHF 286,450 to LPC under the 2018 Commitment Purchase Agreement. The 2018 Commitment Purchase Agreement replaces the 2017 Commitment Purchase Agreement (as defined below), which was terminated as a result of the Merger. Under the 2017 Commitment Purchase Agreement, LPC agreed to subscribe for up to $13,500,000 common shares and prior to its termination, the Company had issued an aggregate of 2,600,000 (pre-merger) common shares for aggregate proceeds of CHF 1.7 million to LPC under the 2017 Commitment Purchase Agreement. The Company had transaction costs amounting to CHF 349,907. The payment of CHF 252,351 was recorded as a derivative financial instrument and classified as a non-current asset and CHF 97,556 to finance expense in the statement of profit or loss and comprehensive loss. During the financial year 2019, the Company had sold 89,880 of its common shares for an aggregate offering price of $ 286,450. The related transaction costs of CHF 2,859 were charged to equity. On January 30, 2018, the Company completed a public offering of 62,499 common shares and concurrent offering of warrants, each warrant entitling its holder to purchase 0.6 common shares (the “January 2018 Registered Offering”). The net proceeds to the Company from the January 2018 Registered Offering were approximately CHF 4.5 million, after deducting placement agent fees and other estimated offering expenses payable by the Company. As of December 31, 2020, the outstanding warrants issued in the January 2018 Registered Offering were exercisable for up to 37,501 common shares (assuming the Company rounds up fractional common shares to the next whole common share) at an exercise price of $100.00 per common share. As of December 31, 2019 the outstanding warrants were exercisable for up to 37,501 common shares at an exercise price of $100.00 per common share. The Company had transaction costs amounting to CHF 654,985. The transaction costs were recorded as CHF 341,226 in equity for the issuance of the common shares and CHF 313,760 to finance expense in the statement of profit or loss and comprehensive loss for the issuance of the warrants. Authorized share capital On January 24, 2019, our board of directors determined that it would be in our best interest to change our legal seat and jurisdiction of incorporation, respectively, from Switzerland to Bermuda (the “Redomestication”). The Company’s Memorandum of Continuance and the Bye-laws that were adopted at an extraordinary meeting of shareholders held on March 8, 2019 provided for an authorized share capital of 200,000,000 common shares and 20,000,000 preference shares. Following a reverse share split at a ratio of 20-for-1 on May 1, 2019, a decision by the annual general meeting of shareholders on June 4, 2020 to increase the authorized share capital and the reduction of the par value of June 30, 2020, our authorized share capital consists of 25,000,000 common shares, par value CHF 0.01 per share, and 20,000,000 preference shares, par value CHF 0.02 per share.

Share-based compensation

Share-based compensation	12 Months Ended
	Dec. 31, 2020
Disclosure of share-based payment arrangements [text block] [Abstract]
Share-based compensation	13. Share-based compensation Description In 2014, the Group introduced an equity incentive plan (the (“EIP”) as amended in 2017 and 2019. In September 2019, all employees and directors of the Company opted-in to forfeit all option grants received prior to 2019 in exchange for new options (the “September 2019 Conversion Grant”). The number of new options was calculated on a value neutral basis using the Black-Scholes model. Including the September 2019 Conversion Grant, the Company granted 390,620 options in 2019 under the EIP. Plan C was terminated in 2019. The last outstanding options under Plan C were replaced by the September 2019 Conversion Grant.” In 2020, the Company granted 726,637 options under the EIP. Holders of vested options are entitled to purchase common shares of the Company. Under the Equity Incentive Plan, the Board of Directors defined the exercise price as the average daily closing price of the Company’s shares during the 30 days preceding the date of grant. All options are to be settled by the physical delivery of shares. The key terms and conditions related to the grants under these programs at December 31, 2020 are as follows: Plan Number of Vesting conditions Contractual Equity Incentive Plan Board 237,083 1 year service from grant date 6 years Equity Incentive Plan Management & Staff 399,738 2 years’ service from grant date (50%) 8 years Equity Incentive Plan Management & Staff 399,738 3 years’ service from grant date (50%) 8 years Measurement of fair values The fair value of the options was measured based on the Black-Scholes formula. Stock Option Plan Equity Incentive Equity Incentive Equity Incentive Equity Incentive Fair value at grant date USD 0.325 1) USD 0.391 1) USD 0.258 2) USD 0.514 2) USD 0.578 2) USD 0.715 1) USD 1.006 1) USD 1.193 1) USD 1.495 2) USD 2.196 2) USD 2.596 2) Share price at grant date USD 0.79 USD 0.92 USD 1.76 USD 3.35 Exercise price USD 0.878 USD 0.825 USD 2.07 USD 5.75 Expected volatility 84.96% 72.72% 119.41% 156.26% Expected life 2 and 3 years 1, 2 and 3 years 1, 2 and 3 years 1, 2 and 3 years Expected dividends — — — — Risk-free interest rate 0.82% 0.61% 1.62% 2.29% 1) October grants for the respective year 2) April grants for the respective year The Company uses its own historic volatility to calculate expected volatility. The expected life of all options is assumed to correspond to the vesting period. The total expense recognized for equity-settled share-based payment transactions were CHF 368,793 in 2020 (2019: CHF 228,920, 2018: CHF 42,757). Share based compensation loss related to employee stock options amounted to CHF 351,401 in 2020 (2019: CHF 226,601, 2018: CHF 27,730). Share based compensation expense of CHF 0 related to the purchase of intangibles was capitalized for the year ended December 31, 2020 (2019: CHF 2,319, 2018: 15,027). The number and weighted average exercise prices (in CHF) of options under the share option programs are as follows: 2020 2019 Number of Weighted average Weighted average Number of Weighted average Weighted average Outstanding at January 1 324,053 3.01 7.60 992,777 1.10 7.45 Replacement of historical grants — — — (992,777 ) — — New grant with new exercise price — — — 39,191 — — Expired during the year — — — — — — Forfeited during the year — — — (66,567 ) — — Exercised during the year — — — — — — Granted during the year 714,484 0.87 — 351,429 3.30 — Outstanding at December 31 1,038,537 1.58 — 324,053 3.01 — Exercisable at December 31 37,576 — 7.01 — — 7.60 The range of exercise prices for outstanding options was CHF 0.73 to CHF 27.93 as of December 31, 2020 and CHF 2.00 to CHF 5.56 as of December 31, 2019.

Trade and other payables

Trade and other payables	12 Months Ended
	Dec. 31, 2020
Disclosure of trade and other payables [text block] [Abstract]
Trade and other payables	14. Trade and other payables December 31, December 31, Trade accounts payable - third parties 722,272 906,501 Other 40,181 31,746 Total trade and other payables 762,453 938,247

Accrued expenses

Accrued expenses	12 Months Ended
	Dec. 31, 2020
Accrued expenses [Abstract]
Accrued expenses	15. Accrued expenses December 31, December 31, Accrued research and development costs including milestone payments 1,105,089 1,019,563 Professional fees 172,273 108,519 Accrued vacation & overtime 44,466 23,377 Employee benefits incl. share based payments 101,821 47,916 Other 9,457 140,447 Total accrued expenses 1,433,106 1,339,822

Research and development expens

Research and development expense	12 Months Ended
	Dec. 31, 2020
Disclosure of research and development expense [text block] [Abstract]
Research and development expense	16. Research and development expense December 31, December 31, December 31, Pre-clinical projects 242,617 182,346 873,453 Clinical projects 476,972 993,085 846,235 Drug manufacturing and substance 614,744 481,453 2,185,292 Employee benefits and expenses 1,120,814 1,373,543 1,652,791 Lease expenses from short-term lease 34,147 26,057 65,921 Patents and trademarks 246,592 168,367 634,986 Regulatory projects 110,612 80,347 398,426 Depreciation tangible assets 16,481 20,083 32,485 Total research and development expense 2,862,979 3,325,281 6,689,589 Research and development expense were capitalized in the amount of CHF 2,343,677 during 2020 compared to CHF 3,230,373 in 2019.

General and administrative expe

General and administrative expense	12 Months Ended
	Dec. 31, 2020
General and administrative expense [Abstract]
General and administrative expense	17. General and administrative expense December 31, December 31, December 31, Employee benefits and expenses 811,373 1,010,708 1,084,112 Business development 95,663 113,959 43,816 Travel expenses 28,898 102,679 70,944 Administration expenses 1,645,530 2,653,914 2,797,526 Lease expenses from short-term lease 13,871 27,362 52,416 Depreciation tangible assets 3,555 10,740 186,520 Capital tax expenses (4,228 ) 14,501 29,200 Total general and administrative expenses 2,594,662 3,933,863 4,264,534

Employee benefits

Employee benefits	12 Months Ended
	Dec. 31, 2020
Disclosure of employee benefits [text block] [Abstract]
Employee benefits	18. Employee benefits December 31, December 31, December 31, Salaries 1,260,359 1,832,382 2,542,952 Pension costs 156,843 130,792 108,978 Other social benefits 116,290 217,448 188,138 Share based payments costs 351,401 226,601 27,730 Other personnel expenditures 47,295 (22,973 ) (130,895 ) Total employee benefits 1,932,188 2,384,250 2,736,903 Benefit plans The Company participates in a retirement plan (the “Plan”) organized as an independent collective foundation, that covers all of its employees in Switzerland, including management. The collective foundation is governed by a foundation board. The board is made up of an equal number of employee and employer representatives of the affiliated companies. The Company has no direct influence on the investment strategy of the collective foundation. Moreover, certain elements of the employee benefits are defined in the same way for all affiliated companies. This is mainly related to the annuity factors at retirement and to interest allocated on retirement savings. The employer itself cannot determine the benefits or how they are financed directly. The foundation board of the collective foundation is responsible for the determination of the investment strategy, for making changes to the pension fund regulations and in particular, also for defining the financing of the pension benefits. The old age benefits are based on retirement savings for each employee, coupled with annual retirement credits and interest (there is no possibility to credit negative interest). At retirement age, the insured members can choose whether to take a pension for life, which includes a spouse’s pension, or a lump sum. In addition to retirement benefits, the plan benefits also include disability and death benefits. Insured members may also buy into the scheme to improve their pension provision up to the maximum amount permitted under the rules of the plan and may withdraw funds early for the purchase of a residential property for their own use subject to limitations under Swiss law. On leaving the Company, retirement savings are transferred to the pension institution of the new employer or to a vested benefits institution. This type of benefit may result in pension payments varying considerably between individual years. In defining the benefits, the minimum requirements of the Swiss Law on Occupational Retirement, Survivors and Disability Pension Plans (BVG) and its implementing provisions must be observed. The BVG defines the minimum pensionable salary and the minimum retirement credits. In Switzerland, the minimum interest rate applicable to these minimum retirement savings is set by the Swiss Federal Council at least once every two years. The rate was 1.00% in 2018, 1.00% in 2019 and 1.00% in 2020. The assets are invested by the collective foundation to which many companies contribute, in a diversified portfolio that respects the requirements of the Swiss BVG. Therefore, disaggregation of the pension assets and presentation of plan assets in classes that distinguish the nature and risks of those assets is not possible. Under the Plan, both the Company and the employee share the costs equally. The structure of the plan and the legal provisions of the BVG mean that the employer is exposed to actuarial risks. The main risks are investment risk, interest risk, disability risk and the risk of longevity. Through the affiliation to a collective foundation, the Company has minimized these risks, since they are shared between a much greater number of participants. For accounting purposes under IFRS, the plan is treated as a defined benefit plan. The following tables present information about the net defined benefit liability and its components: Change in defined benefit obligation 2020 2019 Defined benefit obligation at January 1 3,087,947 3,085,625 Service costs 151,624 138,580 Plan participants’ contribution 76,032 107,618 Interest cost 9,482 27,335 Actuarial losses 58,912 145,385 Transfer-out amounts (201,310 ) (445,457 ) Transfer-in amounts of new employees 346,915 28,861 Defined benefit obligation at December 31 3,529,602 3,087,947 The defined benefit obligation includes only liabilities for active employees. The weighted average modified duration of the defined benefit obligation at December 31, 2020 is 21.9 years (2019: 22.6 years). Change in fair value of plan assets 2020 2019 Fair value of plan assets at January 1 2,327,500 2,437,338 Interest income 7,429 22,198 Return on plan assets excluding interest income 32,794 73,375 Employer contributions 76,032 107,618 Plan participants’ contributions 76,032 107,618 Transfer-out amounts (201,310 ) (445,457 ) Transfer-in amounts of new employees 346,915 28,861 Administration expense (3,166 ) (4,051 ) Fair value of plan assets at December 31 2,662,226 2,327,500 Net defined benefit liability recognized in the statement of financial position December 31, December 31, Present value of funded defined benefit obligation 3,529,602 3,087,947 Fair value of plan assets (2,662,226 ) (2,327,500 ) Net defined benefit liability 867,376 760,447 Defined Benefit Cost 2020 2019 2018 Service cost 151,624 138,580 90,162 Net interest expense 2,053 5,137 14,541 Administration expense 3,166 4,051 6,009 Total defined costs for the year recognized in profit or loss 156,843 147,768 110,712 Remeasurement of the Defined Benefit Liability 2020 2019 2018 Actuarial loss (gain) arising from changes in financial assumptions 13,031 360,541 (119,117 ) Actuarial loss arising from experience adjustments 45,881 (215,156 ) (1,792,265 ) Actuarial gain arising from demographic assumptions — — — Return on plan assets excluding interest income (32,794 ) (73,375 ) 634,190 Total defined benefit cost for the year recognized in the other comprehensive loss 26,118 72,010 (1,277,192 ) Assumptions At December 31 2020 2019 2018 Discount rate 0.20 % 0.30 % 0.95 % Future salary increase 0.60 % 1.10 % 1.10 % Pension indexation 0.00 % 0.00 % 0.00 % Mortality and disability rates BVG2015G BVG2015G BVG2015G Sensitivity analysis Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other assumptions constant, would have affected the defined benefit obligation by the amounts shown below. December 31, 2020 2019 Change in assumption 0.25% increase 0.25% increase Discount rate (166,228) (148,884) Salary increase 13,602 14,395 Pension indexation 88,460 74,976 Change in assumption + 1 year + 1 year Life expectancy 88,215 73,484

Finance income and finance expe

Finance income and finance expense	12 Months Ended
	Dec. 31, 2020
Finance income and finance expense [Abstract]
Finance income and finance expense	19. Finance income and finance expense 2020 2019 2018 Interest income 258 17,882 — Net foreign currency exchange gain 3,207,649 1,343,153 1,103,067 Revaluation gain from derivative financial instruments — 663,725 1,350,071 Total finance income 3,207,907 2,024,760 2,453,138 Interest expense (incl. Bank charges) 135,151 28,628 1,070,177 Net foreign currency exchange loss 3,541,202 1,562,725 1,242,938 Revaluation loss from derivative financial instruments 2,250,222 — — Transaction costs 219,615 — — Total finance expense 6,146,190 1,591,353 2,313,115 Finance (expense)/income, net (2,938,283 ) 433,407 140,023 In 2020, CHF 2,248,257 of the revaluation loss from derivative financial instruments is related to the revaluation of the financial derivatives embedded in the FiveT convertible loan (note 25), both at partial conversion and at year-end. CHF 1,965 of the revaluation loss is related to the revaluation of outstanding warrants from public offerings (note 26). In 2019 and 2018 there was a revaluation gain from derivative financial instruments of CHF 663,725 and CHF 1,350,071 respectively. In 2020, net foreign currency exchange gains contain translation gains of CHF 71,525 (2019: CHF 7,744; 2018: CHF 264,029) which arose on the Company’s USD and EUR denominated cash and cash equivalents. In 2020, finance expenses did not include any interest paid (2019: CHF 3,745; 2018: CHF 435,993).

Taxation

Taxation	12 Months Ended
	Dec. 31, 2020
Taxation [Abstract]
Taxation	20. Taxation The Group’s income tax expense recognized in the consolidated statement of profit or loss and other comprehensive loss was as follows: 2020 2019 2018 Deferred income tax expense (389,384 ) (213,355 ) (294,056 ) Deferred income tax gain 410,668 407,192 131,879 21,284 193,837 (162,177 ) The Group’s effective income tax expense differed from the expected theoretical amount computed by applying the Group’s applicable weighted average tax rate of 12.1% in 2020 (2019: 12.5%, 2018: 21.1%) as summarized in the following table: Reconciliation 2020 2019 2018 Loss before income tax (8,221,449 ) (6,825,738 ) (11,334,224 ) Income tax at statutory tax rates applicable to results in the respective countries 991,120 854,636 2,397,177 Effect of unrecognized temporary differences (302,557 ) 89,974 140,371 Effect of unrecognized taxable losses (184,881 ) (913,309 ) (2,553,594 ) Effect of utilization of previously unrecognized taxable losses — 193,155 — Effect of impairment of deferred tax assets — (131,055 ) — Effect of previously unrecognized deferred tax asset 97,458 20,977 114,116 Effect of expenses deductible for tax purposes — — — Effect of expenses not considerable for tax purposes (47,894 ) (29,549 ) — Effect of changes in local tax legislation and/or local tax rates — 110,758 — Effect of impact from application of different tax rates (531,962 ) (1,750 ) (260,247 ) Effect of unrecognized taxable losses in equity — — — Income tax gain/(loss) 21,284 193,837 (162,177 ) The tax effect of taxable temporary differences that give rise to deferred income tax liabilities or to deferred income tax assets as of December 31 is presented below: Deferred Tax Liabilities December 31, December 31, Intangible assets (252,174 ) (212,844 ) Deferred unrealized foreign exchange gains (350,054 ) — Derivative financial asset (26,156 ) Total (602,228 ) (239,000 ) Deferred Tax Asset December 31, December 31, Net operating loss (NOL) 476,363 91,851 Total 476,363 91,851 Deferred Tax, net (125,865 ) (147,149 ) Deferred Tax 2020 Opening Balance Recognized in Profit or Loss Recognized in Equity Closing Balance Intangible assets (212,844 ) (39,330 ) — (252,174 ) Hercules Loan Facility — — — — Deferred unrealized foreign exchange gains — (350,054 ) — (350,054 ) Derivative financial asset (26,156 ) 26,156 — — Net operating loss (NOL) 91,851 384,512 — 476,363 Total (147,149 ) 21,284 — (125,865 ) Deferred Tax 2019 Opening Balance Recognized in Profit or Loss Recognized in Equity Closing Balance Intangible assets (627,540 ) 414,696 — (212,844 ) Hercules Loan Facility (889 ) 889 — — Derivative financial asset (17,763 ) (8,393 ) — (26,156 ) Net operating loss (NOL) 305,206 (213,355 ) — 91,851 Total (340,986 ) 193,837 — (147,149 ) As of December 31, 2020, the Group had unrecognized tax loss carryforwards amounting to CHF 114.0 million (2019: CHF 151.5 million), of which CHF 113.0 million related to Auris Medical AG, Otolanum AG, Zilentin AG and Altamira Medica AG in Switzerland, CHF 1.0 million to Auris Medical Inc. in the United States and CHF 0.0 million to Auris Medical PTY in Australia (2019: CHF 150.4 million for Auris Medical AG, Auris Medical Holding Ltd. and Otolanum AG and CHF 1.1 million for Auris Medical Inc.). The Group’s unrecognized tax loss carryforwards with their expiry dates are as follows: December 31, December 31, Within 1 year 19,575,171 22,405,533 Between 1 and 3 years 56,866,795 49,120,938 Between 3 and 7 years 36,701,692 78,872,116 More than 7 years 870,200 1,054,465 Total 114,013,858 151,453,052 Due to the uncertainty surrounding the future results of operations and the uncertainty as to whether the Group can use the loss carryforwards for tax purposes, deferred tax assets on tax loss carryforwards were only considered to the extent that they offset taxable temporary differences within the same taxable entity. No deferred tax assets are calculated on temporary differences related to pension obligations from IAS 19. The tax effect of the major unrecognized temporary differences and loss carryforwards is presented in the table below: December 31, December 31, Deductible temporary differences Employee benefit plan 113,106 99,162 Derivative financial instruments 36,973 — Other accounts payable 258,303 — Stock option plans — 568 Total potential tax assets 408,382 99,730 Taxable unrecognized temporary differences Convertible loan 19,359 — Total unrecognized potential tax liabilities 19,359 — Offsetting potential tax liabilities with potential tax assets (19,359 ) — Net potential tax assets from temporary differences not recognized 389,023 99,730 Potential tax assets from loss carry-forwards not recognized 14,896,367 19,611,272 Total potential tax assets from loss carry-forwards and temporary differences not recognized 15,285,390 19,711,002

Loss per share

Loss per share	12 Months Ended
	Dec. 31, 2020
Disclosure of earnings per share [text block] [Abstract]
Loss per share	21. Loss per share December 31, December 31, December 31, Loss attributable to owners of the Company (8,200,165 ) (6,631,901 ) (11,496,401 ) Weighted average number of shares outstanding * 6,014,146 2,909,056 795,043 Basic and diluted loss per share (1.36 ) (2.28 ) (14.46 ) * The basic and diluted loss per share for the year ended December 31, 2018 is revised to reflect the reverse-split ratio of 10 to 1 following the Merger on March 13, 2018 and the reverse-split ratio of 20 to 1 following the “reverse share split” on May 1, 2019. For the years ended December 31, 2020 and 2019 basic and diluted loss per share is based on the weighted average number of shares issued and outstanding and excludes shares to be issued under the Stock Option Plans (Note 13) as they would be anti-dilutive. As of December 31, 2020, the Company has 1,038,537 options outstanding under its stock option plans. The average number of options outstanding between January 1, 2020 and December 31, 2020 was 633,314 (812,167 for the period between January 1, 2019 and December 31, 2019). As of December 31, 2020, the Company had warrants to purchase up to 1,143,537 of its common shares issued and outstanding (as of December 31, 2019, the Company had warrants to purchase up to 2,488,520 common shares).

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Dec. 31, 2020
Commitments and contingencies [Abstract]
Commitments and contingencies	22. Commitments and contingencies Lease commitments The future minimum lease payments under non-cancellable lease term that are not accounted for in the statement of financial position were as follows: December 31, December 31, Within one year 25,580 24,980 Between one and five years — — Total 25,580 24,980 Office lease expenses of CHF 50,260, CHF 49,314 and CHF 118,337 were recorded in 2020, 2019 and 2018, respectively, in the consolidated statement of profit or loss and other comprehensive loss.

Related party transactions

Related party transactions	12 Months Ended
	Dec. 31, 2020
Disclosure of related party [text block] [Abstract]
Related party transactions	23. Related party transactions For purposes of these consolidated financial statements, parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial or operational decisions. Also, parties under common control of the Group are considered to be related. Key management personnel are also related parties. In considering each possible related party relationship, attention is directed to the substance of the relationship, and not merely the legal form. Ante Treuhand AG (“Ante Treuhand”) provides the Chief Financial Officer to the Company. The Chief Financial Officer is an employee of Ante Treuhand and is not paid directly by the Company. Fees paid to Ante Treuhand for CFO services in 2020 were CHF 173,030 (CHF 2019: 11,770). Fees paid to Ante Treuhand for other services provided during the year ended December 31, 2020 were CHF 3,025 (2019: CHF 28,611). Compensation of the members of the Board of Directors and Management In 2020, the total compensation paid to management amounted to CHF 522,237 (2019: CHF 934,179; 2018: CHF 1,403,250). The fees paid to members of the Board of Directors in 2020 for their activities as board members totaled CHF 163,476 (2019: CHF 170,755; 2018: CHF 287,384). Executive Management Board of Directors Total 2020 2019 2018 2020 2019 2018 2020 2019 2018 Short term benefits 407,147 717,905 1,002,707 163,476 170,755 200,421 570,623 888,660 1,203,128 Post-employee benefits years 26,870 42,560 55,278 — — — 26,870 42,560 55,278 Share-based payment charge 204,840 109,912 204,224 57,148 49,323 60,657 261,988 159,235 264,881 Total 638,857 870,377 1,262,209 220,624 220,078 261,078 859,481 1,090,455 1,523,287 In 2020, CHF 261,988 (2019: CHF 159,235; 2018: CHF 264,881) was expensed for grants of stock options to members of the Board of Directors and management. The 2020 share based payment charge shown above excludes adjustments for instruments forfeited in 2020 due to termination of service. Contributions to pension schemes amounted to CHF 26,870, CHF 42,560 and CHF 55,278 during the years 2020, 2019 and 2018, respectively. No termination benefits or other long-term benefits were paid. Members of the Board of Directors and management held 769,101, 271,999 and 703,235 stock options as of December 31, 2020, 2019, and 2018, respectively.

Loan and Warrant

Loan and Warrant	12 Months Ended
	Dec. 31, 2020
Disclosure of borrowings [text block] [Abstract]
Loan and Warrant	24. Loan and Warrant On July 19, 2016, the Company entered into a Loan and Security Agreement (the “Hercules Loan and Security Agreement”) for a secured term loan facility of up to $20.0 million with Hercules Capital, Inc. as administrative agent (“Hercules”) and the lenders party thereto. An initial tranche of $12.5 million was drawn on July 19, 2016, concurrently with the execution of the Hercules Loan and Security Agreement. Prior to its payoff in January 2019, the loan matured on January 2, 2020 and bore interest at a minimum rate of 9.55% per annum and was subject to the variability of the prime interest rate. The loan was secured by a pledge of the shares of Auris Medical AG owned by the Company, all intercompany receivables owed to the Company by its Swiss subsidiaries and a security assignment of the Company’s bank accounts. On April 5, 2018 the Company entered into an agreement with Hercules whereby the terms of the Hercules Loan and Security Agreement were amended to eliminate the $5 million liquidity covenant in exchange for a repayment of $5 million principal amount outstanding under the Hercules Loan and Security Agreement. The loan was initially recognized at transaction value with deductions of the fair value of the warrant at transaction date and directly attributable transactions costs. Subsequent to initial recognition, the loan was measured at amortized cost using the effective interest method. On January 31, 2019, the Company made the final payment to Hercules under the facility, comprising the last amortization payment as well as an end of term charge. With the final payment, all covenants and collaterals in favor of Hercules have been lifted. In addition, Hercules agreed to return the warrant held by Hercules exercisable for 783 common shares at an exercise price of $788.00 per common share for no consideration to the Company in exchange for the Company’s payment to Hercules. Due to the final payment and return of the warrant held by Hercules in January 2019, no warrants were outstanding and subject to revaluation on December 31, 2020. As of December 31, 2019, the fair value of the warrant amounted to CHF 0.00. There was no revaluation gain or loss for the twelve months ended December, 2020 (2019: revaluation gain of CHF 3,804). Since its initial recognition as of July 19, 2016, the fair value decreased by CHF 408,180 resulting in a revaluation gain in the corresponding amount (fair value as of July 19, 2016: CHF 408,180).

Loan

Loan	12 Months Ended
	Dec. 31, 2020
Disclosure Of Loanstext Block [Abstract]
Loan	25. Loan December 31, December 31, Loan guaranteed by Swiss government (COVID-19) 50,000 — Convertible Loan Agreement 473,920 — Total 523,920 — Convertible Loan Agreement December 31, December 31, Gross proceeds at disbursement date 1,500,000 — Embedded derivative, separated (230,974 ) — Transaction costs allocated to host (22,495 ) — Carrying amount at initial recognition 1,246,531 — Converted principal amount (895,455 ) — Accrued interest at 8% 31,920 — Amortization transaction costs and derivative 90,923 — Total 473,920 — On September 7, 2020, our affiliate Altamira Medica AG (“Altamira”) and Auris Medical Holding Ltd. (“the Company”) entered into a convertible loan agreement with FiveT to raise CHF 1,500,000 to fund the initial development of AM-301. The loan has a term of 18 months and carries interest at 8% p.a., which shall not be paid in cash but added to the loan outstanding amount. At maturity, the unconverted outstanding amount of the loan including accrued interest shall become payable in cash. Altamira may choose to repay the total outstanding amount including the accrued interest at 130%, first time after 6 months with a prior written notice of 1 month. Prior to the expiry of the repayment notice period, the lender may convert the repayment amount. Under the convertible loan agreement Five T Capital Holding AG (“FiveT”) has the right to convert the outstanding principal amount including interest into the Company’s common shares or alternatively into Altamira shares. The pricing of a conversion into our common shares is at the lower of 150% of the share price at close of the disbursement date ($1.35 fixed on September 8, 2020) and 95% of the average price of our common share at close of the 5 trading dates preceding the date of the conversion notice. However, the conversion price shall not be less than the higher of the par value and the backward-looking 3-month floor price of 75% of the average closing price of our common shares. The pricing of a conversion into Altamira shares is at the lower of CHF 3.00 and the issue price of a qualified financing round, meaning that a third-party investor will hold at least 10% of Altamira shares after completion of such financing round. The convertible loan agreement further contains a limitation on the conversion rights in the sense that they may not result in an ownership interest of more than 9.99% in the Company or 49.99% in Altamira. By December 31, 2020, an amount of CHF 895,455 has been converted into 737,000 common shares of the Company (at a conversion price of $1.35). The convertible loan is classified as a hybrid contract containing a host that is a financial liability and embedded derivatives separated from the host and measured at fair value with all changes in fair value recognized in profit or loss. The embedded financial derivatives are valued by an independent consultant initially and at period end at fair value, applying a simulation-based valuation approach. The valuation of the embedded financial derivatives is based on input parameters, classified as Level 3. One of the significant inputs is the historical volatility of the Company’s common shares. The underlying share price development has been simulated based on a Geometric Brownian Motion (GBM). In accordance with the GBM definition, a normalized, sustainable level of volatility was applied. The normalized volatility used as per December 31, 2020 was 90.9%, over a lookback period of 12 months. Other significant assumptions relate to the expected exercise date, the expected execution date, the calculation of the repayment amount, as well as assumptions with regards to the early repayment trigger and to the conversion option in Altamira shares. The embedded derivatives of the convertible loan are closely related to each other and are therefore accounted for as a single instrument (i.e., a compound derivative). Due to the conversion based on market share price, the conversion right may result in a variable number of conversion shares and the embedded derivatives are therefore classified as a financial liability. The carrying amount of the host contract at initial recognition is the difference between the carrying amount of the hybrid contract and the fair value of the embedded derivatives. The host is then subsequently measured at amortized cost, using the effective interest rate method. As of December 31, 2020, the carrying amount (including accrued interest) of the host for the unconverted outstanding loan amounted to CHF 473,920 and is included in the balance sheet under non-current liabilities. The fair value of the embedded derivatives of the outstanding loan units amounted to CHF 310,439 and is included in current derivative financial instruments. Expenses related to fair value measurement of embedded derivatives of CHF 2,248,257 as well as effective interest and transaction costs of CHF 127,418 were recorded as financial expenses in profit or loss.

Warrants from Public Offering

Warrants from Public Offering	12 Months Ended
	Dec. 31, 2020
Disclosureof Warrants [Abstract]
Warrants from Public Offering	26. Warrants from Public Offering On February 21, 2017, the Company completed a public offering (the “February 2017 Offering”) of 10,000,000 (pre-merger) common shares with a nominal value of CHF 0.40 each and 10,000,000 (pre-merger) warrants, each warrant entitling its holder to purchase 0.70 of a common share. The net proceeds to the Company from the February 2017 Offering were approximately CHF 9.1 million ($ 9.1 million), after deducting underwriting discounts and other estimated offering expenses payable by us. The Company had transaction costs amounting to CHF 903,919. The transactions costs were recorded as CHF 397,685 in equity for the issuance of the common shares and CHF 506,234 to finance expense in the statement of profit or loss and comprehensive loss for the issuance of the warrants. The underwriter was granted a 30-day option to purchase up to 1,500,000 (pre-merger) additional common shares and/or 1,500,000 (pre-merger) additional warrants. On February 15, 2017, the underwriter partially exercised its 30-day option to purchase additional common shares and/or warrants in the amount of 1,350,000 (pre-merger) warrants. Consequently, the Company issued warrants to purchase up to 7,945,000 (pre-merger) of its common shares at an exercise price of $ 1.20 per share. The warrants are exercisable during a five-year period beginning on date of issuance. The fair value calculation of the warrants is based on the Black-Scholes option price model. Assumptions are made regarding inputs such as volatility and the risk-free rate in order to determine the fair value of the warrant. If a warrant is exercised, the Company will receive variable proceeds because the Company’s functional currency is CHF and the exercise price is in USD, which results in the warrants being considered liability instruments. Therefore, the warrants were assigned fair values using the Black-Scholes model. The residual value was assigned to the common share sold along with each warrant in accordance with IAS 32 Financial instruments. The gross proceeds from the February 2017 offering were CHF 9,998,305 of which CHF 5,091,817 (fair value as of February 21, 2017) was assigned to the warrants and CHF 4,906,488 was assigned to equity. As of December 31, 2020, the outstanding warrants issued in the 2017 February Offering are exercisable for up to 39,725 common shares at an exercise price of $240.00. As of December 31, 2020, the fair value of the warrants amounted to CHF 0.00 (2019: CHF 0.00). As the fair value remained unchanged, no revaluation gain or loss resulted for the year ended December 31, 2020. On January 30, 2018, the Company issued warrants in connection with a direct offering of 62,499 common shares, each warrant entitling its holder to purchase 0.6 common shares at an exercise price of $100.00 per common share. As of December 31, 2020, the outstanding warrants issued in such offering were exercisable for up to 37,501 common shares at an exercise price of $100.00 per common share. As of December 31, 2020 the fair value of the warrants amounted to CHF 6,318 (2019: CHF 4,353). The revaluation loss of the derivative for the twelve months ended December 31, 2020 amounted to CHF 1,965 (2019: revaluation gain of CHF 285,298). Since its initial recognition on January 30, 2018, the fair value of the warrants has decreased by CHF 2,477,429 resulting in a gain in the corresponding amount (fair value as of January 30, 2018: CHF 2,483,747). On July 17, 2018, the Company issued Series A warrants each entitling its holder to purchase 0.35 of a common share for an aggregate of 314,102 common shares, and Series B warrants entitling its holder to purchase 0.25 of a common share for an aggregate of 224,358 common shares in connection with the July 2018 Registered Offering of 897,435 common shares, each warrant entitling its holder to purchase one common share at an original exercise price of CHF 7.80 per common share. Revaluation gain/(loss) show the changes in fair value of the outstanding Series B warrant issued in connection with this offering. As of December 31, 2019, 145,226 Series A warrants were exercised for an aggregate amount of CHF 1,132,762 and 143,221 Series B warrants were exercised for an aggregate amount of CHF 1,117,125. As of December 31, 2019, 143,221 Series B exercised warrants were subject to revaluation at the time that they were exercised and the fair value amounted to CHF 3,005,348. Since its initial recognition on July 17, 2018 the fair value of the warrants has increased by CHF 2,433,099, resulting in a loss in the corresponding amounts (fair value as of July 17, 2018: CHF 572,249). On June 18, 2020, the Series B warrants expired without further warrants being exercised. Due to the expiry on June 18, 2020, no Series B warrants were outstanding and subject to revaluation on December 31, 2020. As of December 31, 2019, the number of Series B warrants outstanding subject to revaluation were 34,535 and the fair value amounted to CHF 0.00. Accordingly, there was no revaluation gain or loss on these warrants for the year ended December 31, 2020 (2019: revaluation gain of CHF 215,572).

Events after the balance sheet

Events after the balance sheet date	12 Months Ended
	Dec. 31, 2020
Events after the balance sheet date [Abstract]
Events after the balance sheet date	27. Events after the balance sheet date The COVID-19 pandemic continues to delay enrollment of patients into our “TRAVERS” phase 2 trial with AM-125. Candidates for trial participation undergo certain types of neurosurgery, which are elective procedures. In early 2021, several sites participating in the “TRAVERS” trial have postponed elective procedures and temporarily reduced or suspended clinical research activities. Although sites are expected to catch up on enrollment once COVID-19 related restrictions are relaxed, the Company expects that final results from the trial will become only available in the third quarter of 2021, at the earliest. On January 15, 2021, we filed a prospectus supplement with the SEC to issue up to $8.0 million in common shares under the at-the-market offering program in place with A.G.P. for a total of $25.0 million. Under the previous registration, we had issued an aggregate of 1,758,618 of our common shares for gross proceeds of approximately $3.25 million. On February 8, 2021, we notified FiveT about our early repayment of the convertible loan as of March 8, 2021. FiveT made use of their right to convert the loan during the notice period and converted the remaining principal plus accrued interest into 516,814 common shares as of March 4, 2021. In August 2019 Xigen, the licensor of the active substance for our Sonsuvi ® ®

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of consolidation	Basis of consolidation Subsidiaries Subsidiaries are entities controlled by the Group. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. Transactions eliminated on consolidation All inter-company balances, transactions and unrealized gains on transactions have been eliminated in consolidation. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.
Segment reporting	Segment reporting A segment is a distinguishable component of the Group that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Group’s other components. The Chief Executive Officer is determined to be the Group’s Chief Operating Decision Maker (“CODM”). The CODM assesses the performance and allocates the resources of the Group as a whole, as all of the Group’s activities are focusing on the development of therapeutics for the treatment and prevention of ear, nose, throat and related disorders. Financial information is only available for the Group as a whole. Therefore, management considers there is only one operating segment under the requirements of IFRS 8, Operating Segments.
Foreign currency	Foreign currency Foreign currency transactions Items included in the financial statements of Group entities are measured using the currency of the primary economic environment in which the entity operates. Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss. Non-monetary items that are measured based on historical cost in a foreign currency are not re-translated. Foreign operations Assets and liabilities of Group entities whose functional currency is other than CHF are included in the consolidation by translating the assets and liabilities into the reporting currency at the exchange rates applicable at the end of the reporting period. Income and expenses are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transaction). These foreign currency translation differences are recognized in Other Comprehensive Loss and presented in the foreign currency translation reserve in equity. When a foreign operation is disposed of such that control is lost, the cumulative amount in the translation reserve related to that foreign operation is reclassified to profit or loss as part of the gain or loss on disposal. Closing rates for the most significant foreign currencies relative to CHF: Currency Geographical area Reporting December 31, December 31, December 31, CHF Swiss Franc Switzerland 5 1.0000 1.0000 1.0000 USD Dollar United States 1 0.8840 0.9674 0.9827 EUR Euro Europe 1 1.0817 1.0855 1.1283 AUD Dollar Australia 1 0.6822 — — Average exchange rates for the year for the most significant foreign currencies relative to CHF: Currency Geographical area Reporting 2020 2019 2018 CHF Swiss Franc Switzerland 5 1.0000 1.0000 1.0000 USD Dollar United States 1 0.9581 0.9938 0.9768 EUR Euro Europe 1 1.0825 1.1128 1.1573 AUD Dollar Australia 1 0.6546 — —
Property and equipment	Property and equipment Property and equipment is measured at historical costs less accumulated depreciation and any accumulated impairment losses. Historical costs include expenditures that are directly attributable to the acquisition of the items. When parts of an item of tangible assets have different useful lives, they are accounted for as separate tangible asset items (major components). Depreciation is calculated on a straight-line basis over the expected useful life of the individual asset or the shorter remaining lease term for leasehold improvements. The applicable estimated useful lives are as follows: Production equipment 5 years Office furniture and electronic data processing equipment (“EDP”) 3 years Leasehold improvements 5 years Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognized. All other repairs and maintenance are charged to profit or loss during the financial period in which they are incurred. Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate. When an asset is reviewed for impairment, the asset’s carrying amount may be written down immediately to its recoverable amount, provided the asset’s carrying amount is greater than its estimated recoverable amount. Management assesses the recoverable amount by assessing the higher of its fair value less costs to sell or its value in use. Cost and accumulated depreciation related to assets retired or otherwise disposed are removed from the accounts at the time of retirement or disposal and any resulting gain or loss is included in profit or loss in the period of disposition.
Intangible assets	Intangible assets Research and development Expenditures on the Group’s research programs are not capitalized, they are expensed when incurred. Expenditures on the Group’s development programs are generally not capitalized except if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group intends to and has sufficient resources to complete development and to use or sell the asset. For the development projects of the Group, these criteria are generally only met when regulatory approval for commercialization is obtained. This has been the general assessment for AM-201, AM-301, AM-101, and AM-111. For the AM-125 program for the treatment of vertigo it is the Group’s assessment that the criteria mentioned above are met and therefore direct development expenditures have been capitalized for AM-125 in 2018, 2019 and 2020. Intellectual property-related costs for patents are part of the expenditure for research and development projects. Therefore, the costs for the prosecution and registration of patents are expensed when incurred as long as the research and development project concerned does not meet the criteria for capitalization. In case of AM-125, where in 2019 a US patent was issued and a related EU application was allowed, prosecution and registration costs have been capitalized as the criteria have been met. Licenses, intellectual property and data rights Intellectual property rights that are acquired by the Group are capitalized as intangible assets if they are controlled by the Group, are separately identifiable and are expected to generate future economic benefits, even if uncertainty exists as to whether the research and development will ultimately result in a marketable product. Consequently, upfront and milestone payments to third parties for the exclusive use of pharmaceutical compounds in specified areas of treatment are recognized as intangible assets. Measurement Intangible assets acquired that have finite useful lives are measured at cost less accumulated amortization and any accumulated impairment losses. Subsequent expenditure Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated goodwill and brands, is recognized in profit or loss as incurred. Amortization All licenses of the Group have finite lives. Amortization will commence once the Group’s intangible assets are available for use which will be the case after regulatory approvals are obtained and the related products are available for use. Amortization of licenses is calculated on a straight-line basis over the period of the expected benefit or until the license expires, whichever is shorter. The estimated useful life is 10 years or the remaining term of patent protection. The Group assesses at each statement of financial position date whether intangible assets which are not yet ready for use are impaired.
Impairment of non-financial assets	Impairment of non-financial assets Property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units). An impairment loss is recognized as the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell or value in use. Impairment losses are recognized in profit or loss. Assets that were previously impaired are reviewed for possible reversal of the impairment at each reporting date. Any increase in the carrying amount of an asset will be based on the depreciated historical costs had the initial impairment not been recognized.
Financial instruments	Financial instruments The Group classifies its financial assets in the following categories: loans and receivables based on the expected loss model. The classification depends on the nature and purpose of the financial assets and is determined at the time of initial recognition. The date of initial application (i.e. the date on which the Company has assessed its existing financial assets and financial liabilities in terms of IFRS 9 requirements) is January 1, 2018. Accordingly, the Company has applied the requirements of IFRS 9 to instruments that continue to be recognized at January 1, 2018 whereas for the year ended December 31, 2017 IAS 39 was applied. Recognition and derecognition of non-derivative financial assets and liabilities The Group initially recognizes loans and receivables and debt securities issued on the date when they are originated. All other financial assets and financial liabilities are initially recognized on the trade date. The Group derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred, or it neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control over the transferred asset. Any interest in such derecognized financial assets that is created or retained by the Group is recognized as a separate asset or liability. The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled, or expired. Financial assets and financial liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Group has a legal right to offset the amounts and intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously. Non-derivative financial assets and liabilities—measurement Loans and receivable These are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Loans and receivables are initially recognized at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, they are measured at amortized cost using the effective interest method, less expected losses. Cash and cash equivalents The Group considers all short-term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to an insignificant risk of changes in value with original maturities of three months or less at the date of the purchase to be cash equivalents. Non-derivative financial liabilities—measurement Non-derivative financial liabilities are initially recognized at fair value less any directly attributable transaction costs. Subsequent to initial recognition, these liabilities are measured at amortized cost using the effective interest method. Convertible loans In a convertible loan classified as a hybrid contract containing a host and a separated embedded derivative, both classified as liability, the carrying amount of the host contract at initial recognition is the difference between the carrying amount of the hybrid contract and the fair value of the embedded derivative. Transaction costs that relate to the issue of the convertible loan are allocated to the host and embedded derivative in proportion to the allocation of the gross proceeds. Transaction costs relating to the embedded derivative are immediately recognized in profit and loss. Transaction costs relating to the host contract are included in the carrying amount of the liability. The host contract is then subsequently measured at amortized cost, using the effective interest method. Share capital All shares of the Company are registered shares and classified as part of shareholders’ equity. Incremental costs directly attributable to the issue of the Company’s shares, net of any tax effects, are recognized as a deduction from equity. The warrants are classified as a financial liability at fair value through profit or loss and the cost allocated to the liability component will be immediately expensed to the income statement. The Company has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future. Repurchase and reissue of ordinary shares (treasury shares) When shares recognized as equity are repurchased, the amount of the consideration paid, which includes directly attributable costs, net of any tax effects, is recognized as a deduction from equity. Repurchased shares are classified as treasury shares and are presented in the treasury share reserve. When treasury shares are sold or reissued subsequently, the amount received is recognized as an increase in equity and the resulting surplus or deficit (calculated as the difference between initial cost and fair value) on the transaction is presented within share premium.
Impairment of non-derivative financial assets	Impairment of non-derivative financial assets Financial assets are assessed at each reporting date to determine whether there is objective evidence of impairment. Objective evidence that financial assets are impaired includes: ● default or delinquency by a debtor; ● indications that a debtor or issuer will enter bankruptcy; ● adverse changes in the payment status of borrowers or issuers; ● the disappearance of an active market for a security; or ● observable data indicating that there is measurable decrease in expected cash flows from a group of financial assets. Financial assets measured at amortized cost The Group considers evidence of impairment for these assets at an individual asset level. An impairment loss is calculated as the difference between an asset’s carrying amount and the present value of the estimated future cash flows discounted at the asset’s original effective interest rate. Losses are recognized in profit or loss and reflected in an allowance account. When the Group considers that there are no realistic prospects of recovery of the asset, the relevant amounts are written off. If the amount of impairment loss subsequently decreases and the decrease can be related objectively to an event occurring after the impairment was recognized, then the previously recognized impairment loss is reversed through profit or loss.
Derivative Financial Instruments	Derivative Financial Instruments Derivative financial instruments (assets) are accounted as the cost to obtain the rights from a third party to issue shares under the purchase agreement and changes in fair value are shown as profit or loss. The fair value calculation of the derivative financial instrument (asset) is adjusted on the utilization of the asset based on total dollar amount of the purchase agreement. Derivative financial instruments (liabilities) are accounted at fair value and changes in fair value are shown as profit or loss. The fair value calculation of the derivative financial instruments is based on the Black-Scholes option pricing model. Assumptions are made for volatility and the risk free rate in order to estimate the fair value of the instrument. Transaction cost related to derivative financial instruments are recorded through profit and loss. Embedded Derivatives Derivatives may be embedded in another contractual arrangement. The Group accounts for an embedded derivative separately from the host contract when: - The host contract is not an asset in the scope of IFRS 9 - The host contract is not itself carried at fair value through profit and loss (FVPL) - The terms of the Embedded Derivative would meet the definition of a derivative if they were contained in a separate contract - The economic characteristics and risks of the embedded derivative are not closely related to the economic characteristics and risks of the host The separated embedded derivatives were measured at fair value by an independent consultant applying a simulation –based valuation approach. Assumptions are made for volatility, risk free rate and other features of the instrument. All changes in the fair value of embedded derivatives were recognized in profit and loss.
Income tax	Income tax Income tax expense comprises current and deferred tax. It is recognized in profit or loss except to the extent that it relates to a business combination, or items recognized directly in equity or in Other Comprehensive Income. Current tax Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to tax payable or receivable in respect of previous years. It is measured using tax rates enacted or substantively enacted at the reporting date. Deferred tax Deferred income tax is recognized, using the balance sheet liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred tax is not recognized for: ● temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss; ● temporary differences related to investments in subsidiaries to the extent that the Group is able to control the timing of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future; and ● taxable temporary differences arising on the initial recognition of goodwill. Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off tax assets against tax liabilities and when they relate to income taxes levied by the same taxation authority and the Group intends to settle its tax assets and liabilities on a net basis.
Employee benefits	Employee benefits The Group maintains a pension plan for all employees in Switzerland through payments to a legally independent collective foundation. This pension plan qualifies under IFRS as defined benefit pension plan. There are no pension plans for the subsidiaries in Ireland, Australia and the United States. The Group’s net obligation in respect of defined benefit plans is calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods, discounting that amount and deducting the fair value of any plan assets. The recognized asset is limited to the present value of economic benefits available in the form of any future refunds from the plan or reductions in future contributions to the plan. In order to calculate the present value of economic benefits, consideration is given to any minimum funding requirements. Remeasurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognized immediately in Other Comprehensive Income. Past service costs, including curtailment gains or losses, are recognized immediately in general and administrative expenses within the operating results. Settlement gains or losses are recognized in general and administrative expenses within the operating results. The Group determines the net interest expense (income) on the net defined benefit liability (asset) for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period or in case of any significant events between measurement dates to the then-net defined benefit liability (asset), taking into account any changes in the net defined benefit liability (asset) during the period as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognized in profit or loss.
Share-based compensation	Share-based compensation The Company maintains a share-based payment plan in the form of a stock option plan for its employees, members of the Board of Directors as well as key service providers. Stock options are granted at the Board’s discretion without any contractual or recurring obligations. The share-based compensation plans qualify as equity settled plans. The grant-date fair value of share-based payment awards granted to employees is recognized as an expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards. Under the Auris Medical Holding Ltd. Long Term Equity Incentive Plan (the “Equity Incentive Plan” or “EIP”), 50% of granted share options granted to employees vest after a period of service of two years from the grant date and the remaining 50% vest after a period of service of three years from the grant date. Share options granted to members of the Board of Directors granted from 2016 onwards vest after a period of one year after the grant date. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that meet the related service and non-market performance conditions at the vesting date. Share-based payments that are not subject to any further conditions are expensed immediately at grant date. In the year the options are exercised the proceeds received net of any directly attributable transaction costs are credited to share capital (par value) and share premium. Valuation of share options Option pricing and values are determined based on the Black Scholes option pricing model and assumptions are made for inputs such as volatility of the Company’s stock and the risk free rate.
Provisions	Provisions Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, where it is more likely than not that an outflow of resources will be required to settle the obligation, and where a reliable estimate can be made of the amount of the obligation. Provisions are not recognized for future operating losses. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability.
Earnings/(loss) per share	Earnings/(loss) per share Basic earnings/(loss) per share are calculated by dividing the net profit/(loss) attributable to owners of the Company by the weighted average number of shares outstanding during the period. Diluted earnings/(loss) per share are calculated by dividing the net profit/(loss) attributable to the owners of the Company by the weighted average number of shares outstanding during the period adjusted for the conversion of all dilutive potential ordinary shares.

Significant accounting polici_2

Significant accounting policies (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of significant accounting policies [Abstract]
Schedule of closing and average exchange rates for the most significant foreign currencies	Currency Geographical area Reporting December 31, December 31, December 31, CHF Swiss Franc Switzerland 5 1.0000 1.0000 1.0000 USD Dollar United States 1 0.8840 0.9674 0.9827 EUR Euro Europe 1 1.0817 1.0855 1.1283 AUD Dollar Australia 1 0.6822 — — Currency Geographical area Reporting 2020 2019 2018 CHF Swiss Franc Switzerland 5 1.0000 1.0000 1.0000 USD Dollar United States 1 0.9581 0.9938 0.9768 EUR Euro Europe 1 1.0825 1.1128 1.1573 AUD Dollar Australia 1 0.6546 — —
Schedule of estimated useful lives	Production equipment 5 years Office furniture and electronic data processing equipment (“EDP”) 3 years Leasehold improvements 5 years

Financial instruments and ris_2

Financial instruments and risk management (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of financial risk management [text block] [Abstract]
Schedule of carrying amounts of financial assets and financial liabilities	December 31, December 31, Financial assets Cash and cash equivalents 11,258,870 1,384,720 Loans and receivables Other receivables 10,040 80,040 Total financial assets 11,268,910 1,464,760 Financial liabilities At amortized cost Trade and other payables 762,453 938,247 Accrued expenses 1,433,106 1,339,822 Loan 523,920 — At fair value through profit and loss Derivative financial instruments 316,757 4,353 Total financial liabilities 3,036,236 2,282,422
Schedule of analysis the remaining contractual maturities of financial liabilities	Carrying Less than Between 2 years Total December 31, 2020 Trade and other payables 762,453 762,453 — — 762,453 Accrued expenses 1,433,106 1,433,106 — — 1,433,106 Loan and borrowings 523,920 473,920 50,000 523,920 Derivative financial instruments 316,757 310,439 — 6,318 316,757 Total 3,036,236 2,979,918 50,000 6,318 3,036,236 Carrying Less than Between 2 years Total December 31, 2019 Trade and other payables 938,247 938,247 — — 938,247 Accrued expenses 1,339,822 1,339,822 — — 1,339,822 Loan and borrowings — — — — — Derivative financial instruments 4,353 — — 4,353 4,353 Total 2,282,422 2,278,069 — 4,353 2,282,422
Schedule of fair value measurement of assets and liabilities and valuation techniques	Fair values as at Fair Financial assets / liabilities December 31, December 31, value Valuation technique(s) and key input(s) Derivative financial liabilities – Warrants from public offerings Liability 6,318 Liability Level 2 Black-Scholes option pricing model The share price is determined by Company’s NASDAQ quoted-price. The strike price and maturity are defined by the contract. The volatility assumption is driven by Company’s historic quoted share price and the risk free rate is estimated based on observable yield curves at the end of each reporting period. Derivative financial liabilities – Embedded derivatives 310,439 — Level 3 Monte Carlo simulation model The valuation is based on input parameters classified as level 3. Input parameters include the historical volatility of AMHL shares, risk-free rate, expected remaining life, expected exercise date and share prices of AMHL at valuation dates. Derivative financial asset Asset Asset Level 3 The fair value is equal to the price paid to the counter party for obtaining the right under the purchase agreement. — 219,615 Subsequent, the fair value is adjusted proportionally for the part of the right consumed.
Schedule of resonably alternative assumptions for the valuation of the option component of the convertible loan	Dec 31, 2020 Dec 31, 2019 Increase/Decrease Effect on result Increase/Decrease Effect on result Change in volatility +5% 2,770 - -5% -5,475 -
Schedule of fair value measurement of derivative financial instrument	Non-cash changes 01.01.2020 Financing 1) Fair Other 2) 31.12.2020 Derivative financial instrument 4,353 — 219,315 93,089 316,757 Loans — 1,522,931 — (999,011 ) 523,920 Total 4,353 1,522,931 219,315 (905,922 ) 840,677 Non-cash changes 01.01.2019 Financing 1) Fair Other 2) 31.12.2019 Derivative financial instrument 675,328 — (663,725 ) (7,250 ) 4,353 Loans 1,435,400 (1,463,328 ) — 27,928 — Total 2,110,728 (1,463,328 ) (663,725 ) 20,678 4,353 1) The financing cash flows are from loan borrowings or loan repayments. 2) Other non-cash changes include recognition of derivative, partial conversion and amortization of convertible loan, accrued interest and Foreign Exchange-Difference.
Schedule of carrying amounts of financial assets and financial liabilities	December 31, December 31, Financial assets Cash and cash equivalents 11,258,870 1,384,720 Other receivables 10,040 80,040 Total 11,268,910 1,464,760
Schedule of quantitative data about the exposure of financial assets and liabilities to currency risk	2020 2019 in CHF USD EUR USD EUR Cash and cash equivalents 9,214,709 694,287 1,041,695 125,631 Other receivables 479 — 154,063 — Trade and other payables (75,712 ) (397,853 ) (51,527 ) (526,637 ) Accrued expenses (34,648 ) (569,400 ) (750,949 ) (175,826 ) Net statement of financial position exposure -asset/(liability) 9,104,828 (272,966 ) 393,282 (576,832 )

Segment information (Tables)

Segment information (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of segment information [Abstract]
Disclosure of operating segments [text block]	December 31, December 31, Switzerland 9,030,778 6,852,286 Australia 151,269 — Total 9,182,047 6,852,286

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of property, plant and equipment [text block] [Abstract]
Schedule of property, plant and equipment	Production Office Total At cost As of January 1, 2019 289,888 233,706 523,594 Additions 63,600 — 63,600 Disposals — — — As of December 31, 2019 353,488 233,706 587,194 Additions — — — Disposals — — — As of December 31, 2020 353,488 233,706 587,194 Accumulated depreciation As of January 1, 2019 (270,408 ) (219,291 ) (489,699 ) Charge for the year (20,083 ) (10,740 ) (30,823 ) Disposals — — — As of December 31, 2019 (290,491 ) (230,031 ) (520,522 ) Charge for the year (16,481 ) (3,555 ) (20,036 ) Disposals — — — As of December 31, 2020 (306,972 ) (233,586 ) (540,558 ) Net book value As of December 31, 2019 62,997 3,675 66,672 As of December 31, 2020 46,516 120 46,636

Intangible assets (Tables)

Intangible assets (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of intangible assets [Abstract]
Disclosure of detailed information about intangible assets [text block]	Licenses IP & Data rights Patents Internally Total At cost As of January 1, 2019 1,482,520 193,989 — 1,858,731 3,535,240 Additions — — 239,593 2,990,780 3,230,373 As of December 31, 2019 1,482,520 193,989 239,593 4,849,511 6,765,613 Exchange differences 6,120 6,120 Additions — — 177,623 2,166,054 2,343,677 As of December 31, 2020 1,482,520 193,989 417,216 7,021,685 9,115,410 Accumulated amortization and impairment losses As of December 31, 2019 — — — — — As of December 31, 2020 — — — — — Net book value As of December 31, 2019 1,482,520 193,989 239,593 4,849,511 6,765,613 As of December 31, 2020 1,482,520 193,989 417,216 7,021,685 9,115,410

Other receivables (Tables)

Other receivables (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of Other receivables [Abstract]
Schedule of other receivables	December 31, December 31, Advance payments to suppliers 479 — Value added tax receivable 38,337 26,438 Withholding tax receivable 6,087 24,113 Deposit credit cards 10,040 80,040 Other 25,918 204,708 Total other receivables 80,861 335,299

Prepayments (Tables)

Prepayments (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of prepayments [Abstract]
Schedule of prepayments	December 31, December 31, Advance payments to suppliers 5,020 40,461 Clinical projects and related activities 164,916 265,842 Insurance 104,590 114,016 Other 3,063 13,912 Total prepayments 277,589 434,231

Cash and cash equivalents (Tabl

Cash and cash equivalents (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of cash and cash equivalents [text block] [Abstract]
Schedule of cash and cash equivalents	December 31, December 31, Cash in bank accounts 11,258,870 1,383,182 Cash on hand — 1,538 Total cash and cash equivalents 11,258,870 1,384,720

Capital and reserves (Tables)

Capital and reserves (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of Capital and reserves [Abstract]
Disclosure of classes of share capital [text block]	December 31, December 31, Number CHF Number CHF Common shares with a par value of CHF 0.01 each 11,417,159 114,172 — — Common shares with a nominal value of CHF 0.40 — — 4,125,949 1,650,380 Total 11,417,159 114,172 4,125,949 1,650,380
Schedule of common shares	Common Shares (Number) 2020 2019 As of January 1 4,125,949 1,775,839 Public offering — 2,161,280 Exercise of warrants 1,263,845 — LPC equity line 1,610,120 89,880 ATM program 1,628,827 98,950 Share-based payments (bonus) 51,418 — Conversion convertible loan 737,000 — Registered direct offering 2,000,000 — Total, as of December 31 11,417,159 4,125,949

Share-based compensation (Table

Share-based compensation (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of share-based payment arrangements [text block] [Abstract]
Schedule of key terms and conditions related to the grants	Plan Number of Vesting conditions Contractual Equity Incentive Plan Board 237,083 1 year service from grant date 6 years Equity Incentive Plan Management & Staff 399,738 2 years’ service from grant date (50%) 8 years Equity Incentive Plan Management & Staff 399,738 3 years’ service from grant date (50%) 8 years
Schedule of fair value of the options measured	Stock Option Plan Equity Incentive Equity Incentive Equity Incentive Equity Incentive Fair value at grant date USD 0.325 1) USD 0.391 1) USD 0.258 2) USD 0.514 2) USD 0.578 2) USD 0.715 1) USD 1.006 1) USD 1.193 1) USD 1.495 2) USD 2.196 2) USD 2.596 2) Share price at grant date USD 0.79 USD 0.92 USD 1.76 USD 3.35 Exercise price USD 0.878 USD 0.825 USD 2.07 USD 5.75 Expected volatility 84.96% 72.72% 119.41% 156.26% Expected life 2 and 3 years 1, 2 and 3 years 1, 2 and 3 years 1, 2 and 3 years Expected dividends — — — — Risk-free interest rate 0.82% 0.61% 1.62% 2.29%
Schedule of number and weighted average exercise prices	2020 2019 Number of Weighted average Weighted average Number of Weighted average Weighted average Outstanding at January 1 324,053 3.01 7.60 992,777 1.10 7.45 Replacement of historical grants — — — (992,777 ) — — New grant with new exercise price — — — 39,191 — — Expired during the year — — — — — — Forfeited during the year — — — (66,567 ) — — Exercised during the year — — — — — — Granted during the year 714,484 0.87 — 351,429 3.30 — Outstanding at December 31 1,038,537 1.58 — 324,053 3.01 — Exercisable at December 31 37,576 — 7.01 — — 7.60

Trade and other payables (Table

Trade and other payables (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of trade and other payables [text block] [Abstract]
Schedule of trade and other payables	December 31, December 31, Trade accounts payable - third parties 722,272 906,501 Other 40,181 31,746 Total trade and other payables 762,453 938,247

Accrued expenses (Tables)

Accrued expenses (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of Accrued expenses [Abstract]
Schedule of accrued expenses	December 31, December 31, Accrued research and development costs including milestone payments 1,105,089 1,019,563 Professional fees 172,273 108,519 Accrued vacation & overtime 44,466 23,377 Employee benefits incl. share based payments 101,821 47,916 Other 9,457 140,447 Total accrued expenses 1,433,106 1,339,822

Research and development expe_2

Research and development expense (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of research and development expense [text block] [Abstract]
Schedule of research and development expense	December 31, December 31, December 31, Pre-clinical projects 242,617 182,346 873,453 Clinical projects 476,972 993,085 846,235 Drug manufacturing and substance 614,744 481,453 2,185,292 Employee benefits and expenses 1,120,814 1,373,543 1,652,791 Lease expenses from short-term lease 34,147 26,057 65,921 Patents and trademarks 246,592 168,367 634,986 Regulatory projects 110,612 80,347 398,426 Depreciation tangible assets 16,481 20,083 32,485 Total research and development expense 2,862,979 3,325,281 6,689,589

General and administrative ex_2

General and administrative expense (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of general and administrative expense [Abstract]
Schedule of general and administrative expense	December 31, December 31, December 31, Employee benefits and expenses 811,373 1,010,708 1,084,112 Business development 95,663 113,959 43,816 Travel expenses 28,898 102,679 70,944 Administration expenses 1,645,530 2,653,914 2,797,526 Lease expenses from short-term lease 13,871 27,362 52,416 Depreciation tangible assets 3,555 10,740 186,520 Capital tax expenses (4,228 ) 14,501 29,200 Total general and administrative expenses 2,594,662 3,933,863 4,264,534

Employee benefits (Tables)

Employee benefits (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of employee benefits [text block] [Abstract]
Schedule of defined benefit plan expense recognized in profit or loss	December 31, December 31, December 31, Salaries 1,260,359 1,832,382 2,542,952 Pension costs 156,843 130,792 108,978 Other social benefits 116,290 217,448 188,138 Share based payments costs 351,401 226,601 27,730 Other personnel expenditures 47,295 (22,973 ) (130,895 ) Total employee benefits 1,932,188 2,384,250 2,736,903
Disclosure of net defined benefit liability (asset) [text block]	2020 2019 Defined benefit obligation at January 1 3,087,947 3,085,625 Service costs 151,624 138,580 Plan participants’ contribution 76,032 107,618 Interest cost 9,482 27,335 Actuarial losses 58,912 145,385 Transfer-out amounts (201,310 ) (445,457 ) Transfer-in amounts of new employees 346,915 28,861 Defined benefit obligation at December 31 3,529,602 3,087,947 2020 2019 Fair value of plan assets at January 1 2,327,500 2,437,338 Interest income 7,429 22,198 Return on plan assets excluding interest income 32,794 73,375 Employer contributions 76,032 107,618 Plan participants’ contributions 76,032 107,618 Transfer-out amounts (201,310 ) (445,457 ) Transfer-in amounts of new employees 346,915 28,861 Administration expense (3,166 ) (4,051 ) Fair value of plan assets at December 31 2,662,226 2,327,500 December 31, December 31, Present value of funded defined benefit obligation 3,529,602 3,087,947 Fair value of plan assets (2,662,226 ) (2,327,500 ) Net defined benefit liability 867,376 760,447
Disclosure of defined benefit plans [text block]	2020 2019 2018 Service cost 151,624 138,580 90,162 Net interest expense 2,053 5,137 14,541 Administration expense 3,166 4,051 6,009 Total defined costs for the year recognized in profit or loss 156,843 147,768 110,712 2020 2019 2018 Actuarial loss (gain) arising from changes in financial assumptions 13,031 360,541 (119,117 ) Actuarial loss arising from experience adjustments 45,881 (215,156 ) (1,792,265 ) Actuarial gain arising from demographic assumptions — — — Return on plan assets excluding interest income (32,794 ) (73,375 ) 634,190 Total defined benefit cost for the year recognized in the other comprehensive loss 26,118 72,010 (1,277,192 ) At December 31 2020 2019 2018 Discount rate 0.20 % 0.30 % 0.95 % Future salary increase 0.60 % 1.10 % 1.10 % Pension indexation 0.00 % 0.00 % 0.00 % Mortality and disability rates BVG2015G BVG2015G BVG2015G
Disclosure of sensitivity analysis for actuarial assumptions [text block]	December 31, 2020 2019 Change in assumption 0.25% increase 0.25% increase Discount rate (166,228) (148,884) Salary increase 13,602 14,395 Pension indexation 88,460 74,976 Change in assumption + 1 year + 1 year Life expectancy 88,215 73,484

Finance income and finance ex_2

Finance income and finance expense (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of finance income and finance expense [Abstract]
Schedule of finance income and finance expense	2020 2019 2018 Interest income 258 17,882 — Net foreign currency exchange gain 3,207,649 1,343,153 1,103,067 Revaluation gain from derivative financial instruments — 663,725 1,350,071 Total finance income 3,207,907 2,024,760 2,453,138 Interest expense (incl. Bank charges) 135,151 28,628 1,070,177 Net foreign currency exchange loss 3,541,202 1,562,725 1,242,938 Revaluation loss from derivative financial instruments 2,250,222 — — Transaction costs 219,615 — — Total finance expense 6,146,190 1,591,353 2,313,115 Finance (expense)/income, net (2,938,283 ) 433,407 140,023

Taxation (Tables)

Taxation (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of Taxation [Abstract]
Schedule of income tax expense	2020 2019 2018 Deferred income tax expense (389,384 ) (213,355 ) (294,056 ) Deferred income tax gain 410,668 407,192 131,879 21,284 193,837 (162,177 )
Schedule of major components of tax expense (income)	Reconciliation 2020 2019 2018 Loss before income tax (8,221,449 ) (6,825,738 ) (11,334,224 ) Income tax at statutory tax rates applicable to results in the respective countries 991,120 854,636 2,397,177 Effect of unrecognized temporary differences (302,557 ) 89,974 140,371 Effect of unrecognized taxable losses (184,881 ) (913,309 ) (2,553,594 ) Effect of utilization of previously unrecognized taxable losses — 193,155 — Effect of impairment of deferred tax assets — (131,055 ) — Effect of previously unrecognized deferred tax asset 97,458 20,977 114,116 Effect of expenses deductible for tax purposes — — — Effect of expenses not considerable for tax purposes (47,894 ) (29,549 ) — Effect of changes in local tax legislation and/or local tax rates — 110,758 — Effect of impact from application of different tax rates (531,962 ) (1,750 ) (260,247 ) Effect of unrecognized taxable losses in equity — — — Income tax gain/(loss) 21,284 193,837 (162,177 )
Schedule of deferred taxes	Deferred Tax Liabilities December 31, December 31, Intangible assets (252,174 ) (212,844 ) Deferred unrealized foreign exchange gains (350,054 ) — Derivative financial asset (26,156 ) Total (602,228 ) (239,000 ) Deferred Tax Asset December 31, December 31, Net operating loss (NOL) 476,363 91,851 Total 476,363 91,851 Deferred Tax, net (125,865 ) (147,149 )
Schedule of recognized tax benefits deferred tax	Deferred Tax 2020 Opening Balance Recognized in Profit or Loss Recognized in Equity Closing Balance Intangible assets (212,844 ) (39,330 ) — (252,174 ) Hercules Loan Facility — — — — Deferred unrealized foreign exchange gains — (350,054 ) — (350,054 ) Derivative financial asset (26,156 ) 26,156 — — Net operating loss (NOL) 91,851 384,512 — 476,363 Total (147,149 ) 21,284 — (125,865 ) Deferred Tax 2019 Opening Balance Recognized in Profit or Loss Recognized in Equity Closing Balance Intangible assets (627,540 ) 414,696 — (212,844 ) Hercules Loan Facility (889 ) 889 — — Derivative financial asset (17,763 ) (8,393 ) — (26,156 ) Net operating loss (NOL) 305,206 (213,355 ) — 91,851 Total (340,986 ) 193,837 — (147,149 )
Schedule of tax loss carry-forwards	December 31, December 31, Within 1 year 19,575,171 22,405,533 Between 1 and 3 years 56,866,795 49,120,938 Between 3 and 7 years 36,701,692 78,872,116 More than 7 years 870,200 1,054,465 Total 114,013,858 151,453,052
Schedule of tax effect of major unrecognized temporary differences	December 31, December 31, Deductible temporary differences Employee benefit plan 113,106 99,162 Derivative financial instruments 36,973 — Other accounts payable 258,303 — Stock option plans — 568 Total potential tax assets 408,382 99,730 Taxable unrecognized temporary differences Convertible loan 19,359 — Total unrecognized potential tax liabilities 19,359 — Offsetting potential tax liabilities with potential tax assets (19,359 ) — Net potential tax assets from temporary differences not recognized 389,023 99,730 Potential tax assets from loss carry-forwards not recognized 14,896,367 19,611,272 Total potential tax assets from loss carry-forwards and temporary differences not recognized 15,285,390 19,711,002

Loss per share (Tables)

Loss per share (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of earnings per share [text block] [Abstract]
Schedule of loss per share	December 31, December 31, December 31, Loss attributable to owners of the Company (8,200,165 ) (6,631,901 ) (11,496,401 ) Weighted average number of shares outstanding * 6,014,146 2,909,056 795,043 Basic and diluted loss per share (1.36 ) (2.28 ) (14.46 )

Commitments and contingencies (

Commitments and contingencies (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of commitments and contingencies [Abstract]
Disclosure of maturity analysis of operating lease payments [text block]	December 31, December 31, Within one year 25,580 24,980 Between one and five years — — Total 25,580 24,980

Related party transactions (Tab

Related party transactions (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of related party [text block] [Abstract]
Schedule of related party transaction	Executive Management Board of Directors Total 2020 2019 2018 2020 2019 2018 2020 2019 2018 Short term benefits 407,147 717,905 1,002,707 163,476 170,755 200,421 570,623 888,660 1,203,128 Post-employee benefits years 26,870 42,560 55,278 — — — 26,870 42,560 55,278 Share-based payment charge 204,840 109,912 204,224 57,148 49,323 60,657 261,988 159,235 264,881 Total 638,857 870,377 1,262,209 220,624 220,078 261,078 859,481 1,090,455 1,523,287

Loan (Tables)

Loan (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure Of Loanstext Block [Abstract]
Schedule of loan	December 31, December 31, Loan guaranteed by Swiss government (COVID-19) 50,000 — Convertible Loan Agreement 473,920 — Total 523,920 —
Schedule of convertible loan agreement	December 31, December 31, Gross proceeds at disbursement date 1,500,000 — Embedded derivative, separated (230,974 ) — Transaction costs allocated to host (22,495 ) — Carrying amount at initial recognition 1,246,531 — Converted principal amount (895,455 ) — Accrued interest at 8% 31,920 — Amortization transaction costs and derivative 90,923 — Total 473,920 —

Reporting entity (Details)

Reporting entity (Details) - 12 months ended Dec. 31, 2020	CHF (SFr)	EUR (€)	USD ($)
Auris Medical AG [Member]
Reporting entity (Details) [Line Items]
Name of subsidiary	Auris Medical AG
Principal place of business	Basel
Country of incorporation	Switzerland
Ownership percentage in subsidiary	100.00%
Share capital of subsidiary	SFr 2,500,000
Equity reverse stock split, description	Following the Merger, Auris NewCo, the surviving company, had a share capital of CHF 122,347.76, divided into 6,117,388 (pre-2019 Reverse Share Split) common shares with a nominal value of CHF 0.02 (pre-2019 Reverse Share Split) each. Pursuant to the Merger, the Company’s shareholders received one common share with a nominal value of CHF 0.02 (pre-2019 Reverse Share Split) of Auris NewCo for every 10 of the Company’s common shares held prior to the Merger, effectively resulting in a “reverse stock split” at a ratio of 10-for-1.
Otolanum AG [Member]
Reporting entity (Details) [Line Items]
Name of subsidiary	Otolanum AG
Principal place of business	Zug
Country of incorporation	Switzerland
Ownership percentage in subsidiary	100.00%
Share capital of subsidiary	SFr 100,000
Zilentin AG [Member]
Reporting entity (Details) [Line Items]
Name of subsidiary	Zilentin AG
Principal place of business	Zug
Country of incorporation	Switzerland
Ownership percentage in subsidiary	100.00%
Share capital of subsidiary	SFr 100,000
Altamira Medica AG [Member]
Reporting entity (Details) [Line Items]
Name of subsidiary	Altamira Medica AG
Principal place of business	Zug
Country of incorporation	Switzerland
Ownership percentage in subsidiary	100.00%
Share capital of subsidiary	SFr 1,000,000
Auris Medical Inc [Member]
Reporting entity (Details) [Line Items]
Name of subsidiary	Auris Medical Inc
Country of incorporation	United States
Ownership percentage in subsidiary	100.00%
Share capital of subsidiary | $			$ 15,000
Auris Medical Ltd [Member]
Reporting entity (Details) [Line Items]
Name of subsidiary	Auris Medical Ltd
Principal place of business	Dublin
Country of incorporation	Ireland
Ownership percentage in subsidiary	100.00%
Share capital of subsidiary | €		€ 100
Auris Medial Pty Ltd [Member]
Reporting entity (Details) [Line Items]
Name of subsidiary	Auris Medical Pty Ltd
Principal place of business	Collingwood
Country of incorporation	Australia
Ownership percentage in subsidiary	100.00%
Share capital of subsidiary | $			$ 100

Basis of preparation (Details)

Basis of preparation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Basis of preparation (Details) [Line Items]
Reverse stock split	The Company effected the 2019 Reverse Share Split of its common shares at a ratio of 1-for-20.
Tax asset	$ 476,363	$ 91,851
Bottom of range [member]
Basis of preparation (Details) [Line Items]
Tax losses years	7 years
Top of range [member]
Basis of preparation (Details) [Line Items]
Tax losses years	20 years

Significant accounting polici_3

Significant accounting policies (Details)	12 Months Ended
	Dec. 31, 2020
Significant accounting policies (Details) [Line Items]
Number of operating segments	1
Description of equity incentive plan	Under the Auris Medical Holding Ltd. Long Term Equity Incentive Plan (the “Equity Incentive Plan” or “EIP”), 50% of granted share options granted to employees vest after a period of service of two years from the grant date and the remaining 50% vest after a period of service of three years from the grant date. Share options granted to members of the Board of Directors granted from 2016 onwards vest after a period of one year after the grant date.
License [member]
Significant accounting policies (Details) [Line Items]
Estimated useful life	10 years

Significant accounting polici_4

Significant accounting policies (Details) - Schedule of closing and average exchange rates for the most significant foreign currencies	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Switzerland [Member]
Significant accounting policies (Details) - Schedule of closing and average exchange rates for the most significant foreign currencies [Line Items]
Reporting entities	5
Closing rate	1	1	1
Average exchange rate	1	1	1
United States [Member]
Significant accounting policies (Details) - Schedule of closing and average exchange rates for the most significant foreign currencies [Line Items]
Reporting entities	1
Closing rate	0.8840	0.9674	0.9827
Average exchange rate	0.9581	0.9938	0.9768
Europe [Member]
Significant accounting policies (Details) - Schedule of closing and average exchange rates for the most significant foreign currencies [Line Items]
Reporting entities	1
Closing rate	1.0817	1.0855	1.1283
Average exchange rate	1.0825	1.1128	1.1573
Australia [Member]
Significant accounting policies (Details) - Schedule of closing and average exchange rates for the most significant foreign currencies [Line Items]
Reporting entities	1
Closing rate	0.6822
Average exchange rate	0.6546

Significant accounting polici_5

Significant accounting policies (Details) - Schedule of estimated useful lives	12 Months Ended
	Dec. 31, 2020
Production equipment [Member]
Significant accounting policies (Details) - Schedule of estimated useful lives [Line Items]
Useful life	5 years
Office furniture and electronic data processing equipment (“EDP”) [member]
Significant accounting policies (Details) - Schedule of estimated useful lives [Line Items]
Useful life	3 years
Leasehold improvements [member]
Significant accounting policies (Details) - Schedule of estimated useful lives [Line Items]
Useful life	5 years

Financial instruments and ris_3

Financial instruments and risk management (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Financial instruments and risk management (Details) [Line Items]
Increase or decrease in rate (as a percent)	5.00%
USD [Member]
Financial instruments and risk management (Details) [Line Items]
Increase or decrease in rate (as a percent)		5.00%
Impact of increase or decrease in rate on net result	SFr 455,241	SFr 19,664
EUR [member]
Financial instruments and risk management (Details) [Line Items]
Increase or decrease in rate (as a percent)		5.00%
Impact of increase or decrease in rate on net result	SFr 13,648	SFr 28,841

Financial instruments and ris_4

Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities [Line Items]
Financial assets	$ 11,268,910	$ 1,464,760
Financial liabilities	3,036,236	2,282,422
Cash And Cash Equivalents [member]
Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities [Line Items]
Financial assets	11,258,870	1,384,720
Loans and receivables [Member]
Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities [Line Items]
Financial assets
Other receivables [Member]
Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities [Line Items]
Financial assets	10,040	80,040
Financial liabilities at amortised cost, category [member] | Trade And Other Payables [Member]
Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities [Line Items]
Financial liabilities	762,453	938,247
Financial liabilities at amortised cost, category [member] | Accrued Expenses [Member]
Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities [Line Items]
Financial liabilities	1,433,106	1,339,822
Financial liabilities at amortised cost, category [member] | Loans1 [member]
Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities [Line Items]
Financial liabilities	523,920
At fair value through profit and loss [member]
Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities [Line Items]
Financial liabilities	$ 316,757	$ 4,353

Financial instruments and ris_5

Financial instruments and risk management (Details) - Schedule of analysis the remaining contractual maturities of financial liabilities - CHF (SFr)	Dec. 31, 2020	Dec. 31, 2019
Financial instruments and risk management (Details) - Schedule of analysis the remaining contractual maturities of financial liabilities [Line Items]
Trade and other payables	SFr 762,453	SFr 938,247
Accrued expenses	1,433,106	1,339,822
Loan and borrowings	523,920
Derivative financial instruments	316,757	4,353
Total	3,036,236	2,282,422
Carrying amount [Member]
Financial instruments and risk management (Details) - Schedule of analysis the remaining contractual maturities of financial liabilities [Line Items]
Trade and other payables	762,453	938,247
Accrued expenses	1,433,106	1,339,822
Loan and borrowings	523,920
Derivative financial instruments	316,757	4,353
Total	3,036,236	2,282,422
Less than 3 months [Member]
Financial instruments and risk management (Details) - Schedule of analysis the remaining contractual maturities of financial liabilities [Line Items]
Trade and other payables	762,453	938,247
Accrued expenses	1,433,106	1,339,822
Loan and borrowings	473,920
Derivative financial instruments	310,439
Total	2,979,918	2,278,069
Between 3 months and 2 years [Member]
Financial instruments and risk management (Details) - Schedule of analysis the remaining contractual maturities of financial liabilities [Line Items]
Trade and other payables
Accrued expenses
Loan and borrowings	50,000
Derivative financial instruments
Total	50,000
2 years and later [Member]
Financial instruments and risk management (Details) - Schedule of analysis the remaining contractual maturities of financial liabilities [Line Items]
Trade and other payables
Accrued expenses
Loan and borrowings
Derivative financial instruments	6,318	4,353
Total	SFr 6,318	SFr 4,353

Financial instruments and ris_6

Financial instruments and risk management (Details) - Schedule of fair value measurement of assets and liabilities and valuation techniques - CHF (SFr)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Level 2 [Member] | Derivative Financial Instruments, Liabilities [Member]
Financial instruments and risk management (Details) - Schedule of fair value measurement of assets and liabilities and valuation techniques [Line Items]
Derivative financial liabilities– Warrants from public offerings	Liability 6,318	Liability 4,353
Level 3 [Member] | Derivative Financial Instruments, Liabilities [Member]
Financial instruments and risk management (Details) - Schedule of fair value measurement of assets and liabilities and valuation techniques [Line Items]
Derivative financial liabilities – Embedded derivatives	SFr 310,439
Level 3 [Member] | Derivative Financial Instruments, Assets [Member]
Financial instruments and risk management (Details) - Schedule of fair value measurement of assets and liabilities and valuation techniques [Line Items]
Derivative financial assets		SFr 219,615

Financial instruments and ris_7

Financial instruments and risk management (Details) - Schedule of resonably alternative assumptions for the valuation of the option component of the convertible loan - CHF (SFr)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Financial instruments and risk management (Details) - Schedule of resonably alternative assumptions for the valuation of the option component of the convertible loan [Line Items]
Increase/Decrease in volatility assumption	(5.00%)
Effect on result before taxes on (in Francs)	SFr (5,475)
Change in volatility [Member]
Financial instruments and risk management (Details) - Schedule of resonably alternative assumptions for the valuation of the option component of the convertible loan [Line Items]
Increase/Decrease in volatility assumption	5.00%
Effect on result before taxes on (in Francs)	SFr 2,770

Financial instruments and ris_8

Financial instruments and risk management (Details) - Schedule of fair value measurement of derivative financial instrument - CHF (SFr)		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019
Financial instruments and risk management (Details) - Schedule of fair value measurement of derivative financial instrument [Line Items]
Balance		SFr 4,353	SFr 2,110,728
Financing Cash Flows	[1]	1,522,931	(1,463,328)
Fair value revaluation		219,315	(663,725)
Other changes	[2]	(905,922)	20,678
Balance		840,677	4,353
Derivative financial instrument [Member]
Financial instruments and risk management (Details) - Schedule of fair value measurement of derivative financial instrument [Line Items]
Balance		4,353	675,328
Financing Cash Flows	[1]
Fair value revaluation		219,315	(663,725)
Other changes	[2]	93,089	(7,250)
Balance		316,757	4,353
Loans [Member]
Financial instruments and risk management (Details) - Schedule of fair value measurement of derivative financial instrument [Line Items]
Balance			1,435,400
Financing Cash Flows	[1]	1,522,931	(1,463,328)
Fair value revaluation
Other changes	[2]	(999,011)	27,928
Balance		SFr 523,920
[1]	The financing cash flows are from loan borrowings or loan repayments.
[2]	Other non-cash changes include recognition of derivative, partial conversion and amortization of convertible loan, accrued interest and Foreign Exchange-Difference.

Financial instruments and ris_9

Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities [Line Items]
Maximum exposure to credit risk	$ 11,268,910	$ 1,464,760
Cash and cash equivalents [Member]
Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities [Line Items]
Maximum exposure to credit risk	11,258,870	1,384,720
Other receivables [Member]
Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities [Line Items]
Maximum exposure to credit risk	$ 10,040	$ 80,040

Financial instruments and ri_10

Financial instruments and risk management (Details) - Schedule of quantitative data about the exposure of financial assets and liabilities to currency risk	Dec. 31, 2020EUR (€)	Dec. 31, 2020USD ($)	Dec. 31, 2019EUR (€)	Dec. 31, 2019USD ($)
Financial instruments and risk management (Details) - Schedule of quantitative data about the exposure of financial assets and liabilities to currency risk [Line Items]
Net statement of financial position exposure -asset/(liability)	€ (272,966)	$ 9,104,828	€ (576,832)	$ 393,282
Trade and other payables [Member]
Financial instruments and risk management (Details) - Schedule of quantitative data about the exposure of financial assets and liabilities to currency risk [Line Items]
Net statement of financial position exposure -asset/(liability)	(397,853)	(75,712)	(526,637)	(51,527)
Accrued Expenses [Member]
Financial instruments and risk management (Details) - Schedule of quantitative data about the exposure of financial assets and liabilities to currency risk [Line Items]
Net statement of financial position exposure -asset/(liability)	(569,400)	(34,648)	(175,826)	(750,949)
Cash and Cash Equivalents [Member]
Financial instruments and risk management (Details) - Schedule of quantitative data about the exposure of financial assets and liabilities to currency risk [Line Items]
Net statement of financial position exposure -asset/(liability)	€ 694,287	9,214,709	125,631	1,041,695
Other Receivables [Member]
Financial instruments and risk management (Details) - Schedule of quantitative data about the exposure of financial assets and liabilities to currency risk [Line Items]
Net statement of financial position exposure -asset/(liability)		$ 479		$ 154,063

Segment information (Details) -

Segment information (Details) - Schedule of operating segments - CHF (SFr)	Dec. 31, 2020	Dec. 31, 2019
Segment information (Details) - Schedule of operating segments [Line Items]
Non-current assets	SFr 9,182,047	SFr 6,852,286
Switzerland [Member]
Segment information (Details) - Schedule of operating segments [Line Items]
Non-current assets	9,030,778	SFr 6,852,286
Australia [Member]
Segment information (Details) - Schedule of operating segments [Line Items]
Non-current assets	SFr 151,269

Property and Equipment (Details

Property and Equipment (Details) - Schedule of property, plant and equipment - CHF (SFr)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
At cost [Member]
Property and Equipment (Details) - Schedule of property, plant and equipment [Line Items]
Property, plant and equipment	SFr 587,194	SFr 523,594
Additions		63,600
Disposals
Property, plant and equipment	587,194	587,194
Accumulated depreciation [Member]
Property and Equipment (Details) - Schedule of property, plant and equipment [Line Items]
Property, plant and equipment	(520,522)	(489,699)
Additions	(20,036)	(30,823)
Disposals
Property, plant and equipment	(540,558)	(520,522)
Net book value [Member]
Property and Equipment (Details) - Schedule of property, plant and equipment [Line Items]
Property, plant and equipment	66,672
Property, plant and equipment	46,636	66,672
Production equipment [Member] | At cost [Member]
Property and Equipment (Details) - Schedule of property, plant and equipment [Line Items]
Property, plant and equipment	353,488	289,888
Additions		63,600
Disposals
Property, plant and equipment	353,488	353,488
Production equipment [Member] | Accumulated depreciation [Member]
Property and Equipment (Details) - Schedule of property, plant and equipment [Line Items]
Property, plant and equipment	(290,491)	(270,408)
Additions	(16,481)	(20,083)
Disposals
Property, plant and equipment	(306,972)	(290,491)
Production equipment [Member] | Net book value [Member]
Property and Equipment (Details) - Schedule of property, plant and equipment [Line Items]
Property, plant and equipment	62,997
Property, plant and equipment	46,516	62,997
Office furniture and EDP [Member] | At cost [Member]
Property and Equipment (Details) - Schedule of property, plant and equipment [Line Items]
Property, plant and equipment	233,706	233,706
Additions
Disposals
Property, plant and equipment	233,706	233,706
Office furniture and EDP [Member] | Accumulated depreciation [Member]
Property and Equipment (Details) - Schedule of property, plant and equipment [Line Items]
Property, plant and equipment	(230,031)	(219,291)
Additions	(3,555)	(10,740)
Disposals
Property, plant and equipment	(233,586)	(230,031)
Office furniture and EDP [Member] | Net book value [Member]
Property and Equipment (Details) - Schedule of property, plant and equipment [Line Items]
Property, plant and equipment	3,675
Property, plant and equipment	SFr 120	SFr 3,675

Intangible assets (Details)

Intangible assets (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2013	Dec. 06, 2018	Jul. 30, 2017
Intangible assets (Details) [Line Items]
Capitalize prosecution and registration costs	SFr 177,623	SFr 239,593
Capitalized amount	SFr 2,343,677	SFr 3,230,373
License [Member] | At cost [Member]
Intangible assets (Details) [Line Items]
Milestone payment intangible			SFr 1,125,000
IP & Data rights [Member]
Intangible assets (Details) [Line Items]
Intangible assets				SFr 47,409
IP & Data rights [Member] | At cost [Member]
Intangible assets (Details) [Line Items]
Intangible assets					SFr 146,580

Intangible assets (Details) - S

Intangible assets (Details) - Schedule of intangible assets - CHF (SFr)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Intangible assets (Details) - Schedule of intangible assets [Line Items]
Additions		SFr 3,230,373
At cost [Member]
Intangible assets (Details) - Schedule of intangible assets [Line Items]
Intangible Assets, Beginning Balance	SFr 6,765,613	3,535,240
Exchange differences	6,120
Additions	2,343,677
Intangible Assets, Ending Balance	9,115,410	6,765,613
Accumulated amortization and impairment losses [Member]
Intangible assets (Details) - Schedule of intangible assets [Line Items]
Accumulated amortization and impairment losses
Net book value [Member]
Intangible assets (Details) - Schedule of intangible assets [Line Items]
Intangible Assets, Ending Balance	6,765,613
Intangible Assets, Ending Balance	9,115,410	6,765,613
Licenses [Member]
Intangible assets (Details) - Schedule of intangible assets [Line Items]
Additions
Licenses [Member] | At cost [Member]
Intangible assets (Details) - Schedule of intangible assets [Line Items]
Intangible Assets, Beginning Balance	1,482,520	1,482,520
Additions
Intangible Assets, Ending Balance	1,482,520	1,482,520
Licenses [Member] | Accumulated amortization and impairment losses [Member]
Intangible assets (Details) - Schedule of intangible assets [Line Items]
Accumulated amortization and impairment losses
Licenses [Member] | Net book value [Member]
Intangible assets (Details) - Schedule of intangible assets [Line Items]
Intangible Assets, Ending Balance	1,482,520
Intangible Assets, Ending Balance	1,482,520	1,482,520
IP & Data rights [Member]
Intangible assets (Details) - Schedule of intangible assets [Line Items]
Additions
IP & Data rights [Member] | At cost [Member]
Intangible assets (Details) - Schedule of intangible assets [Line Items]
Intangible Assets, Beginning Balance	193,989	193,989
Additions
Intangible Assets, Ending Balance	193,989	193,989
IP & Data rights [Member] | Accumulated amortization and impairment losses [Member]
Intangible assets (Details) - Schedule of intangible assets [Line Items]
Accumulated amortization and impairment losses
IP & Data rights [Member] | Net book value [Member]
Intangible assets (Details) - Schedule of intangible assets [Line Items]
Intangible Assets, Ending Balance	193,989
Intangible Assets, Ending Balance	193,989	193,989
Patents [Member]
Intangible assets (Details) - Schedule of intangible assets [Line Items]
Additions		239,593
Patents [Member] | At cost [Member]
Intangible assets (Details) - Schedule of intangible assets [Line Items]
Intangible Assets, Beginning Balance	239,593
Additions	177,623
Intangible Assets, Ending Balance	417,216	239,593
Patents [Member] | Accumulated amortization and impairment losses [Member]
Intangible assets (Details) - Schedule of intangible assets [Line Items]
Accumulated amortization and impairment losses
Patents [Member] | Net book value [Member]
Intangible assets (Details) - Schedule of intangible assets [Line Items]
Intangible Assets, Ending Balance	239,593
Intangible Assets, Ending Balance	417,216	239,593
Internally generated [Member]
Intangible assets (Details) - Schedule of intangible assets [Line Items]
Additions		2,990,780
Internally generated [Member] | At cost [Member]
Intangible assets (Details) - Schedule of intangible assets [Line Items]
Intangible Assets, Beginning Balance	4,849,511	1,858,731
Exchange differences	6,120
Additions	2,166,054
Intangible Assets, Ending Balance	7,021,685	4,849,511
Internally generated [Member] | Accumulated amortization and impairment losses [Member]
Intangible assets (Details) - Schedule of intangible assets [Line Items]
Accumulated amortization and impairment losses
Internally generated [Member] | Net book value [Member]
Intangible assets (Details) - Schedule of intangible assets [Line Items]
Intangible Assets, Ending Balance	4,849,511
Intangible Assets, Ending Balance	SFr 7,021,685	SFr 4,849,511

Other receivables (Details) - S

Other receivables (Details) - Schedule of other receivables - CHF (SFr)	Dec. 31, 2020	Dec. 31, 2019
Schedule of other receivables [Abstract]
Advance payments to suppliers	SFr 479
Value added tax receivable	38,337	SFr 26,438
Withholding tax receivable	6,087	24,113
Deposit credit cards	10,040	80,040
Other	25,918	204,708
Total other receivables	SFr 80,861	SFr 335,299

Prepayments (Details) - Schedul

Prepayments (Details) - Schedule of prepayments - CHF (SFr)	Dec. 31, 2020	Dec. 31, 2019
Schedule of prepayments [Abstract]
Advance payments to suppliers	SFr 5,020	SFr 40,461
Clinical projects and related activities	164,916	265,842
Insurance	104,590	114,016
Other	3,063	13,912
Total prepayments	SFr 277,589	SFr 434,231

Cash and cash equivalents (Deta

Cash and cash equivalents (Details) - Schedule of cash and cash equivalents - CHF (SFr)	Dec. 31, 2020	Dec. 31, 2019
Schedule of cash and cash equivalents [Abstract]
Cash in bank accounts	SFr 11,258,870	SFr 1,383,182
Cash on hand		1,538
Total cash and cash equivalents	SFr 11,258,870	SFr 1,384,720

Capital and reserves (Details)

Capital and reserves (Details) $ / shares in Units, $ in Millions

Dec. 03, 2020

Dec. 01, 2020CHF (SFr)shares

May 15, 2019

Jan. 24, 2019

Dec. 11, 2018

May 02, 2018

Jan. 30, 2018

Apr. 23, 2020

Dec. 31, 2020CHF (SFr)shares

Dec. 31, 2020USD ($)shares

Jul. 17, 2018

Dec. 01, 2020$ / shares

Disclosure of share capital, reserves and other equity interest [text block] [Abstract]

Securities purchase agreements description

the Company entered into securities purchase agreements with several institutional investors for the purchase and sale of 2,000,000 common shares at an offering price of $4.00 per share, pursuant to a registered direct offering. The net proceeds of the offering were approximately $7.3 million.

Conversion amount | SFr

SFr 895,455

Conversion shares

737,000

Conversion price | $ / shares

$ 1.35

Description of purchase agreement

Pursuant to the purchase agreement, LPC agreed to subscribe for up to USD 10,000,000 of our common shares over the 30-month term of the purchase agreement. In 2020, we issued 1,200,000 of our common shares to LPC for an aggregate amount of USD 1.1 million. The 2020 Commitment Purchase Agreement replaced the 2018 Commitment Purchase Agreement. Under the 2018 Commitment Purchase Agreement agreed to purchase common shares for up to $10,000,000 over the 30-month term of the Purchase Agreement. Prior to its termination we had issued 587,500 common shares for aggregate proceeds of $1.8 million to LPC under the LPC Purchase Agreement. The Purchase Agreement replaced the Purchase Agreement that we entered into with LPC on October 10, 2017 (the “2017 Commitment Purchase Agreement”), which was terminated as a result of the Merger. Under the 2017 Commitment Purchase Agreement, LPC agreed to subscribe for up to $13,500,000 of our common shares, and prior to its termination, we had issued an aggregate of 2,600,000 (pre-merger) common shares for aggregate proceeds of $1.8 million to LPC under the 2017 Commitment Purchase Agreement.

Description of public offering

the Company completed a public offering of (i) 440,000 common shares with a par value of CHF 0.40 each, together with warrants to purchase 440,000 common shares, and (ii) 1,721,280 pre-funded warrants, with each pre-funded warrant exercisable for one common share, together with warrants to purchase 1,721,280 common shares, including 110,000 common shares and warrants to purchase 110,000 common shares sold pursuant to a partial exercise by the underwriters of the underwriters’ over-allotment option (the “May 2019 Registered Offering”). The exercise price for the pre-funded warrants was CHF 0.01 per common share and for the warrants CHF 4.34. The net proceeds to us from the May 2019 Registered Offering were approximately $7.7 million, after deducting underwriting discounts and other offering expenses payable by us. All pre-funded warrants were exercised in 2019. In December 2020, 1,263,845 warrants were exercised, leaving 897,435 warrants outstanding as of December 31, 2020. These remaining warrants were exercised in March 2021.

the Company completed a public offering of 897,435 common shares with a nominal value of CHF 0.40, Series A warrants each entitling its holder to purchase 0.35 of a common share for an aggregate of 314,102 common shares, and Series B warrants entitling its holder to purchase 0.25 of a common share for an aggregate of 224,358 common shares (the “July 2018 Registered Offering”). As of December 31, 2019, the exercise price for the Series A Warrants was CHF 7.80 per common share and the exercise price for the Series B Warrants was CHF 3.95 per common share (which exercise price was automatically adjusted due to the May 2019 Registered Offering). Since the July 2018 Registered Offering, certain Series A warrant holders exercised their warrant shares to purchase 145,226 common shares of the Company and certain Series B warrant holders exercised warrant shares to purchase 143,221 common shares. On June 30, 2020, the Series B warrants expired without further warrants being exercised. The net proceeds to the Company from the July 2018 Registered Offering were approximately CHF 6.2 million, after deducting underwriting discounts and other offering expenses payable by us. The Company had transaction costs amounting to CHF 851,692. The transaction costs were recorded as CHF 742,833 in equity for the issuance of common shares and CHF 108,809 to finance expense in the statement of profit or loss and comprehensive loss for the issuance of the warrants.

Offering price | $

$ 25

Sale of common stock

1,628,827

1,628,827

Common shares for an aggregate

1,758,618

1,758,618

Aggregate offering price | $

$ 3.2

Sale of stock

98,954

98,954

Aggregate offering price | $

$ 978,415

Transaction costs | SFr

SFr 71,161

Commitment purchase agreement, description

On November 27, 2018 and December 11, 2018, the Company entered into purchase agreements with FiveT Capital AG, providing for the issuance and sale by us of an aggregate of 165,750 of its common shares for an aggregate purchase price of CHF 1.6 million in two separate registered direct offerings.

the compnay entered into a purchase agreement (the “2018 Commitment Purchase Agreement”) and a registration rights agreement (the “2018 Registration Rights Agreement”) with Lincoln Park Capital LLC (“LPC”). Pursuant to the 2018 Commitment Purchase Agreement, LPC agreed to purchase common shares for up to $10,000,000 over the 30-month term of the 2018 Commitment Purchase Agreement. As of the date of these consolidated financial statements, the Company has issued an aggregate of 89,880 common shares for aggregate proceeds of CHF 286,450 to LPC under the 2018 Commitment Purchase Agreement. The 2018 Commitment Purchase Agreement replaces the 2017 Commitment Purchase Agreement (as defined below), which was terminated as a result of the Merger. Under the 2017 Commitment Purchase Agreement, LPC agreed to subscribe for up to $13,500,000 common shares and prior to its termination, the Company had issued an aggregate of 2,600,000 (pre-merger) common shares for aggregate proceeds of CHF 1.7 million to LPC under the 2017 Commitment Purchase Agreement. The Company had transaction costs amounting to CHF 349,907. The payment of CHF 252,351 was recorded as a derivative financial instrument and classified as a non-current asset and CHF 97,556 to finance expense in the statement of profit or loss and comprehensive loss. During the financial year 2019, the Company had sold 89,880 of its common shares for an aggregate offering price of $ 286,450. The related transaction costs of CHF 2,859 were charged to equity.

Description of Memorandum of Continuance

The Company’s Memorandum of Continuance and the Bye-laws that were adopted at an extraordinary meeting of shareholders held on March 8, 2019 provided for an authorized share capital of 200,000,000 common shares and 20,000,000 preference shares. Following a reverse share split at a ratio of 20-for-1 on May 1, 2019, a decision by the annual general meeting of shareholders on June 4, 2020 to increase the authorized share capital and the reduction of the par value of June 30, 2020, our authorized share capital consists of 25,000,000 common shares, par value CHF 0.01 per share, and 20,000,000 preference shares, par value CHF 0.02 per share.

the Company completed a public offering of 62,499 common shares and concurrent offering of warrants, each warrant entitling its holder to purchase 0.6 common shares (the “January 2018 Registered Offering”). The net proceeds to the Company from the January 2018 Registered Offering were approximately CHF 4.5 million, after deducting placement agent fees and other estimated offering expenses payable by the Company. As of December 31, 2020, the outstanding warrants issued in the January 2018 Registered Offering were exercisable for up to 37,501 common shares (assuming the Company rounds up fractional common shares to the next whole common share) at an exercise price of $100.00 per common share. As of December 31, 2019 the outstanding warrants were exercisable for up to 37,501 common shares at an exercise price of $100.00 per common share. The Company had transaction costs amounting to CHF 654,985. The transaction costs were recorded as CHF 341,226 in equity for the issuance of the common shares and CHF 313,760 to finance expense in the statement of profit or loss and comprehensive loss for the issuance of the warrants.

Capital and reserves (Details)

Capital and reserves (Details) - Schedule of issued share capital - CHF (SFr)	Dec. 31, 2020	Dec. 31, 2019
Capital and reserves (Details) - Schedule of issued share capital [Line Items]
Number	11,417,159	4,125,949
Value (CHF)	SFr 114,172	SFr 1,650,380
Ordinary Shares [Member]
Capital and reserves (Details) - Schedule of issued share capital [Line Items]
Number	11,417,159
Value (CHF)	SFr 114,172
Ordinary Shares Nominal Value [member]
Capital and reserves (Details) - Schedule of issued share capital [Line Items]
Number		4,125,949
Value (CHF)		SFr 1,650,380

Capital and reserves (Details_2

Capital and reserves (Details) - Schedule of issued share capital (Parentheticals) - SFr / shares	Dec. 31, 2020	Dec. 31, 2019
Ordinary Shares [Member]
Capital and reserves (Details) - Schedule of issued share capital (Parentheticals) [Line Items]
Nominal value of common shares	SFr 0.01	SFr 0.01
Ordinary Shares Nominal Value [member]
Capital and reserves (Details) - Schedule of issued share capital (Parentheticals) [Line Items]
Nominal value of common shares	SFr 0.40	SFr 0.40

Capital and reserves (Details_3

Capital and reserves (Details) - Schedule of common shares - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Schedule of common shares [Abstract]
Beginning balance	4,125,949	1,775,839
Ending balance	11,417,159	4,125,949
Public offering		2,161,280
Exercise of warrants	1,263,845
LPC equity line	1,610,120	89,880
ATM program	1,628,827	98,950
Share-based payments (bonus)	51,418
Conversion convertible loan	737,000
Registered direct offering	2,000,000

Share-based compensation (Detai

Share-based compensation (Details)	12 Months Ended
	Dec. 31, 2020CHF (SFr)SFr / sharesshares	Dec. 31, 2019CHF (SFr)SFr / sharesshares	Dec. 31, 2018CHF (SFr)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Share-based compensation (Details) [Line Items]
Options granted (in Shares) | shares	726,637	390,620
Share based payment | SFr	SFr 368,793	SFr 228,920	SFr 42,757
Total expense recognized for equity-settled share-based payment transactions | SFr	SFr 351,401	SFr 226,601	27,730
Purchase of intangibles was capitalized			SFr 15,027	$ 0	$ 2,319
Bottom of range [member]
Share-based compensation (Details) [Line Items]
Stock options exercise price (in Francs per share) | SFr / shares	SFr 0.73	SFr 2
Top of range [member]
Share-based compensation (Details) [Line Items]
Stock options exercise price (in Francs per share) | SFr / shares	SFr 27.93	SFr 5.56

Share-based compensation (Det_2

Share-based compensation (Details) - Schedule of key terms and conditions related to the grants	12 Months Ended
	Dec. 31, 2020
Share-based compensation (Details) - Schedule of key terms and conditions related to the grants [Line Items]
Number of options outstanding	237,083
Vesting conditions	1 year service from grant date
Contractual life of options	6 years
Equity Incentive Plan Employees / Board [Member]
Share-based compensation (Details) - Schedule of key terms and conditions related to the grants [Line Items]
Number of options outstanding	399,738
Vesting conditions	2 years' service from grant date (50%)
Contractual life of options	8 years
Equity Incentive Plan Employees / Board One [Member]
Share-based compensation (Details) - Schedule of key terms and conditions related to the grants [Line Items]
Number of options outstanding	399,738
Vesting conditions	3 years' service from grant date (50%)
Contractual life of options	8 years

Share-based compensation (Det_3

Share-based compensation (Details) - Schedule of fair value of the options measured - USD ($)		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019
One Year Vesting Period [Member] | Equity Incentive Plan 2020 [Member]
Share-based compensation (Details) - Schedule of fair value of the options measured [Line Items]
Fair value at grant date	[1]	USD 0.325 (2 year vesting) 1) USD 0.391 (3 year vesting) 1)
Share price at grant date		USD 0.79
Exercise price		USD 0.878
Expected volatility		84.96%
Expected life		2 and 3 years
Expected dividends
Risk-free interest rate		0.82%
One Year Vesting Period [Member] | Equity Incentive Plan 2019 [Member]
Share-based compensation (Details) - Schedule of fair value of the options measured [Line Items]
Fair value at grant date	[1]		USD 0.715 (1 year vesting) 1) USD 1.006 (2 year vesting) 1) USD 1.193 (3 year vesting) 1)
Share price at grant date			USD 1.76
Exercise price			USD 2.07
Expected volatility			119.41%
Expected life			1, 2 and 3 years
Expected dividends
Risk-free interest rate			1.62%
Two Year Vesting Period [Member] | Equity Incentive Plan 2020 [Member]
Share-based compensation (Details) - Schedule of fair value of the options measured [Line Items]
Fair value at grant date	[2]	USD 0.258 (1 year vesting) 2) USD 0.514 (2 year vesting) 2) USD 0.578 (3 year vesting) 2)
Share price at grant date		USD 0.92
Exercise price		USD 0.825
Expected volatility		72.72%
Expected life		1, 2 and 3 years
Expected dividends
Risk-free interest rate		0.61%
Two Year Vesting Period [Member] | Equity Incentive Plan 2019 [Member]
Share-based compensation (Details) - Schedule of fair value of the options measured [Line Items]
Fair value at grant date	[2]		USD 1.495 (1 year vesting) 2) USD 2.196 (2 year vesting) 2) USD 2.596 (3 year vesting) 2)
Share price at grant date			USD 3.35
Exercise price			USD 5.75
Expected volatility			156.26%
Expected life			1, 2 and 3 years
Expected dividends
Risk-free interest rate			2.29%
[1]	October grants for the respective year
[2]	April grants for the respective year

Share-based compensation (Det_4

Share-based compensation (Details) - Schedule of number and weighted average exercise prices - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Schedule of number and weighted average exercise prices [Abstract]
Number of options, Outstanding	324,053	992,777
Weighted average exercise price, Outstanding (in Dollars per share)	$ 3.01	$ 1.10
Weighted average remaining term, Outstanding	7 years 219 days	7 years 164 days
Number of options, Replacement of historical grants		(992,777)
Number of options, New grant with new exercise price		39,191
Number of options, Expired during the year
Weighted average exercise price, Expired during the year (in Dollars per share)
Number of options, Forfeited during the year		(66,567)
Weighted average exercise price, Forfeited during the year (in Dollars per share)
Number of options, Exercised during the year
Weighted average exercise price, Exercised during the year (in Dollars per share)
Number of options, Granted during the year	714,484	351,429
Weighted average exercise price, Granted during the year (in Dollars per share)	$ 0.87	$ 3.30
Number of options, Outstanding	1,038,537	324,053
Weighted average exercise price, Outstanding (in Dollars per share)	$ 1.58	$ 3.01
Number of options, Exercisable	37,576
Weighted average exercise price, Exercisable (in Dollars per share)
Weighted average remaining term, Exercisable	7 years 3 days	7 years 219 days

Trade and other payables (Detai

Trade and other payables (Details) - Schedule of trade and other payables - CHF (SFr)	Dec. 31, 2020	Dec. 31, 2019
Schedule of trade and other payables [Abstract]
Trade accounts payable - third parties	SFr 722,272	SFr 906,501
Other	40,181	31,746
Total trade and other payables	SFr 762,453	SFr 938,247

Accrued expenses (Details) - Sc

Accrued expenses (Details) - Schedule of accrued expenses - CHF (SFr)	Dec. 31, 2020	Dec. 31, 2019
Schedule of accrued expenses [Abstract]
Accrued research and development costs including milestone payments	SFr 1,105,089	SFr 1,019,563
Professional fees	172,273	108,519
Accrued vacation & overtime	44,466	23,377
Employee benefits incl. share based payments	101,821	47,916
Other	9,457	140,447
Total accrued expenses	SFr 1,433,106	SFr 1,339,822

Research and development expe_3

Research and development expense (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure of research and development expense [text block] [Abstract]
Research and development expense capitalized	SFr 2,343,677	SFr 3,230,373

Research and development expe_4

Research and development expense (Details) - Schedule of research and development expense - CHF (SFr)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of research and development expense [Abstract]
Pre-clinical projects	SFr 242,617	SFr 182,346	SFr 873,453
Clinical projects	476,972	993,085	846,235
Drug manufacturing and substance	614,744	481,453	2,185,292
Employee benefits and expenses	1,120,814	1,373,543	1,652,791
Lease expenses from short-term lease	34,147	26,057	65,921
Patents and trademarks	246,592	168,367	634,986
Regulatory projects	110,612	80,347	398,426
Depreciation tangible assets	16,481	20,083	32,485
Total research and development expense	SFr 2,862,979	SFr 3,325,281	SFr 6,689,589

General and administrative ex_3

General and administrative expense (Details) - Schedule of general and administrative expense - CHF (SFr)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of general and administrative expense [Abstract]
Employee benefits and expenses	SFr 811,373	SFr 1,010,708	SFr 1,084,112
Business development	95,663	113,959	43,816
Travel expenses	28,898	102,679	70,944
Administration expenses	1,645,530	2,653,914	2,797,526
Lease expenses from short-term lease	13,871	27,362	52,416
Depreciation tangible assets	3,555	10,740	186,520
Capital tax expenses	(4,228)	14,501	29,200
Total general and administrative expenses	SFr 2,594,662	SFr 3,933,863	SFr 4,264,534

Employee benefits (Details)

Employee benefits (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of employee benefits [text block] [Abstract]
Benefit plans interest rate	1.00%	1.00%	1.00%
Weighted average duration defined benefit obligation	21 years 328 days	22 years 219 days

Employee benefits (Details) - S

Employee benefits (Details) - Schedule of defined benefit plan expense recognized in profit or loss - CHF (SFr)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of defined benefit plan expense recognized in profit or loss [Abstract]
Salaries	SFr 1,260,359	SFr 1,832,382	SFr 2,542,952
Pension costs	156,843	130,792	108,978
Other social benefits	116,290	217,448	188,138
Share based payments costs	351,401	226,601	27,730
Other personnel expenditures	47,295	(22,973)	(130,895)
Total employee benefits	SFr 1,932,188	SFr 2,384,250	SFr 2,736,903

Employee benefits (Details) -_2

Employee benefits (Details) - Schedule of net defined benefit liability (asset) - CHF (SFr)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of net defined benefit liability (asset) [Abstract]
Defined benefit obligation	SFr 3,087,947	SFr 3,085,625
Fair value of plan assets	2,327,500	2,437,338
Present value of funded defined benefit obligation	3,529,602	3,087,947
Fair value of plan assets	(2,662,226)	(2,327,500)
Defined benefit obligation	867,376	760,447
Service costs	151,624	138,580
Plan participants' contribution	76,032	107,618
Interest cost	9,482	27,335
Actuarial losses	58,912	145,385
Transfer-out amounts	(201,310)	(445,457)
Transfer-in amounts of new employees	346,915	28,861
Defined benefit obligation	3,529,602	3,087,947	SFr 3,085,625
Interest income	7,429	22,198
Return on plan assets excluding interest income	32,794	73,375	(634,190)
Employer contributions	76,032	107,618
Plan participants' contributions	76,032	107,618
Transfer-out amounts	(201,310)	(445,457)
Transfer-in amounts of new employees	346,915	28,861
Administration expense	(3,166)	(4,051)
Fair value of plan assets	SFr 2,662,226	SFr 2,327,500	SFr 2,437,338

Employee benefits (Details) -_3

Employee benefits (Details) - Schedule of defined benefit plans - CHF (SFr)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of defined benefit plans [Abstract]
Service cost	SFr 151,624	SFr 138,580	SFr 90,162
Net interest expense	2,053	5,137	14,541
Administration expense	3,166	4,051	6,009
Total defined costs for the year recognized in profit or loss	156,843	147,768	110,712
Actuarial loss (gain) arising from changes in financial assumptions	13,031	360,541	(119,117)
Actuarial loss arising from experience adjustments	45,881	(215,156)	(1,792,265)
Actuarial gain arising from demographic assumptions
Return on plan assets excluding interest income	(32,794)	(73,375)	634,190
Total defined benefit cost for the year recognized in the other comprehensive loss	SFr 26,118	SFr 72,010	SFr (1,277,192)
Discount rate	0.20%	0.30%	0.95%
Future salary increase	0.60%	1.10%	1.10%
Pension indexation	0.00%	0.00%	0.00%
Mortality and disability rates	BVG2015G	BVG2015G	BVG2015G

Employee benefits (Details) -_4

Employee benefits (Details) - Schedule of sensitivity analysis for actuarial assumptions - CHF (SFr)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Employee benefits (Details) - Schedule of sensitivity analysis for actuarial assumptions [Line Items]
Percentage of reasonably possible increase in actuarial assumption	0.25% increase	0.25% increase
Discount rate [Member]
Employee benefits (Details) - Schedule of sensitivity analysis for actuarial assumptions [Line Items]
Discount rate	SFr (166,228)	SFr (148,884)
Salary increase [Member]
Employee benefits (Details) - Schedule of sensitivity analysis for actuarial assumptions [Line Items]
Discount rate	13,602	14,395
Pension indexation [Member]
Employee benefits (Details) - Schedule of sensitivity analysis for actuarial assumptions [Line Items]
Discount rate	SFr 88,460	SFr 74,976
Change in assumption [Member]
Employee benefits (Details) - Schedule of sensitivity analysis for actuarial assumptions [Line Items]
Life expectancy reasonably possible increase in actuarial assumption	+ 1 year	+ 1 year
Life expectancy {Member]
Employee benefits (Details) - Schedule of sensitivity analysis for actuarial assumptions [Line Items]
Discount rate	SFr 88,215	SFr 73,484

Finance income and finance ex_3

Finance income and finance expense (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of finance income (cost) [text block] [Abstract]
Derivative financial instruments	SFr 2,248,257	SFr 663,725	SFr 1,350,071
Revaluation loss	1,965
Net foreign currency exchange gains	SFr 71,525	7,744	264,029
Interest expenses include interest paid		SFr 3,745	SFr 435,993

Finance income and finance ex_4

Finance income and finance expense (Details) - Schedule of finance income and finance expense - CHF (SFr)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of finance income and finance expense [Abstract]
Interest income	SFr 258	SFr 17,882
Net foreign currency exchange gain	3,207,649	1,343,153	SFr 1,103,067
Revaluation gain from derivative financial instruments		663,725	1,350,071
Total finance income	3,207,907	2,024,760	2,453,138
Interest expense (incl. Bank charges)	135,151	28,628	1,070,177
Net foreign currency exchange loss	3,541,202	1,562,725	1,242,938
Revaluation loss from derivative financial instruments	2,250,222
Transaction costs	219,615
Total finance expense	6,146,190	1,591,353	2,313,115
Finance (expense)/income, net	SFr (2,938,283)	SFr 433,407	SFr 140,023

Taxation (Details)

Taxation (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of income tax [text block] [Abstract]
Weighted average tax rate	12.10%	12.50%	21.10%
Gross tax loss carry forwards, description	the Group had unrecognized tax loss carryforwards amounting to CHF 114.0 million (2019: CHF 151.5 million), of which CHF 113.0 million related to Auris Medical AG, Otolanum AG, Zilentin AG and Altamira Medica AG in Switzerland, CHF 1.0 million to Auris Medical Inc. in the United States and CHF 0.0 million to Auris Medical PTY in Australia (2019: CHF 150.4 million for Auris Medical AG, Auris Medical Holding Ltd. and Otolanum AG and CHF 1.1 million for Auris Medical Inc.).

Taxation (Details) - Schedule o

Taxation (Details) - Schedule of income tax expense - CHF (SFr)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of income tax expense [Abstract]
Deferred income tax expense	SFr (389,384)	SFr (213,355)	SFr (294,056)
Deferred income tax gain	410,668	407,192	131,879
Total	SFr 21,284	SFr 193,837	SFr (162,177)

Taxation (Details) - Schedule_2

Taxation (Details) - Schedule of major components of tax expense (income) - CHF (SFr)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of major components of tax expense (income) [Abstract]
Loss before income tax	SFr (8,221,449)	SFr (6,825,738)	SFr (11,334,224)
Income tax at statutory tax rates applicable to results in the respective countries	991,120	854,636	2,397,177
Effect of unrecognized temporary differences	(302,557)	89,974	140,371
Effect of unrecognized taxable losses	(184,881)	(913,309)	(2,553,594)
Effect of utilization of previously unrecognized taxable losses		193,155
Effect of impairment of deferred tax assets		(131,055)
Effect of previously unrecognized deferred tax asset	97,458	20,977	114,116
Effect of expenses deductible for tax purposes
Effect of expenses not considerable for tax purposes	(47,894)	(29,549)
Effect of changes in local tax legislation and/or local tax rates		110,758
Effect of impact from application of different tax rates	(531,962)	(1,750)	(260,247)
Effect of unrecognized taxable losses in equity
Income tax gain/(loss)	SFr 21,284	SFr 193,837	SFr (162,177)

Taxation (Details) - Schedule_3

Taxation (Details) - Schedule of deferred taxes - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Taxation (Details) - Schedule of deferred taxes [Line Items]
Deferred Tax Liabilities	$ (602,228)	$ (239,000)
Deferred Tax Asset	476,363	91,851
Deferred Tax, net	(125,865)	(147,149)
Intangible assets [Member]
Taxation (Details) - Schedule of deferred taxes [Line Items]
Deferred Tax Liabilities	(252,174)	(212,844)
Deferred unrealized foreign exchange gains [Member]
Taxation (Details) - Schedule of deferred taxes [Line Items]
Deferred Tax Liabilities	(350,054)
Derivative financial asset [Member]
Taxation (Details) - Schedule of deferred taxes [Line Items]
Deferred Tax Liabilities		(26,156)
Net operating loss [Member]
Taxation (Details) - Schedule of deferred taxes [Line Items]
Deferred Tax Asset	$ 476,363	$ 91,851

Taxation (Details) - Schedule_4

Taxation (Details) - Schedule of recognized tax benefits deferred tax - CHF (SFr)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Taxation (Details) - Schedule of recognized tax benefits deferred tax [Line Items]
Opening Balance	SFr (147,149)	SFr (340,986)
Recognized in Profit or Loss	21,284	193,837
Recognized in Equity
Closing Balance	(125,865)	(147,149)
Intangible assets [Member]
Taxation (Details) - Schedule of recognized tax benefits deferred tax [Line Items]
Opening Balance	(212,844)	(627,540)
Recognized in Profit or Loss	(39,330)	414,696
Recognized in Equity
Closing Balance	(252,174)	(212,844)
Deferred unrealized foreign exchange gains [Member]
Taxation (Details) - Schedule of recognized tax benefits deferred tax [Line Items]
Recognized in Profit or Loss	(350,054)
Closing Balance	(350,054)
Derivative financial asset [Member]
Taxation (Details) - Schedule of recognized tax benefits deferred tax [Line Items]
Opening Balance	(26,156)	(17,763)
Recognized in Profit or Loss	26,156	(8,393)
Recognized in Equity
Closing Balance		(26,156)
Hercules Loan Facility [Member]
Taxation (Details) - Schedule of recognized tax benefits deferred tax [Line Items]
Opening Balance		(889)
Recognized in Profit or Loss		889
Recognized in Equity
Net operating loss [Member]
Taxation (Details) - Schedule of recognized tax benefits deferred tax [Line Items]
Opening Balance	91,851	305,206
Recognized in Profit or Loss	384,512	(213,355)
Recognized in Equity
Closing Balance	SFr 476,363	SFr 91,851

Taxation (Details) - Schedule_5

Taxation (Details) - Schedule of tax loss carry-forwards - CHF (SFr)	Dec. 31, 2020	Dec. 31, 2019
Taxation (Details) - Schedule of tax loss carry-forwards [Line Items]
Total tax loss carry-forwards	SFr 114,013,858	SFr 151,453,052
Within 1 year [Member]
Taxation (Details) - Schedule of tax loss carry-forwards [Line Items]
Total tax loss carry-forwards	19,575,171	22,405,533
Between 1 and 3 years [Member]
Taxation (Details) - Schedule of tax loss carry-forwards [Line Items]
Total tax loss carry-forwards	56,866,795	49,120,938
Between 3 and 7 years [Member]
Taxation (Details) - Schedule of tax loss carry-forwards [Line Items]
Total tax loss carry-forwards	36,701,692	78,872,116
More than 7 years [Member]
Taxation (Details) - Schedule of tax loss carry-forwards [Line Items]
Total tax loss carry-forwards	SFr 870,200	SFr 1,054,465

Taxation (Details) - Schedule_6

Taxation (Details) - Schedule of tax effect of major unrecognized temporary differences - CHF (SFr)	Dec. 31, 2020	Dec. 31, 2019
Deductible temporary differences
Employee benefit plan	SFr 113,106	SFr 99,162
Derivative financial instruments	36,973
Other accounts payable	258,303
Stock option plans		568
Total potential tax assets	408,382	99,730
Taxable unrecognized temporary differences
Convertible loan	19,359
Total unrecognized potential tax liabilities	19,359
Offsetting potential tax liabilities with potential tax assets	(19,359)
Net potential tax assets from temporary differences not recognized	389,023	99,730
Potential tax assets from loss carry-forwards not recognized	14,896,367	19,611,272
Total potential tax assets from loss carry-forwards and temporary differences not recognized	SFr 15,285,390	SFr 19,711,002

Loss per share (Details)

Loss per share (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure of earnings per share [text block] [Abstract]
Antidilutive securities excluded from computation of earnings per share, Amount	1,038,537
Average number of options outstanding	633,314	812,167
Warrant to purchase of common stock	1,143,537
Warrants to purchase		2,488,520

Loss per share (Details) - Sche

Loss per share (Details) - Schedule of loss per share		12 Months Ended
		Dec. 31, 2020CHF (SFr)SFr / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019CHF (SFr)SFr / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018CHF (SFr)SFr / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares
Schedule of loss per share [Abstract]
Loss attributable to owners of the Company		SFr (8,200,165)	$ (8,200,165)	SFr (6,631,901)	$ (6,631,901)	SFr (11,496,401)	$ (11,496,401)
Weighted average number of shares outstanding	[1]	6,014,146	6,014,146	2,909,056	2,909,056	795,043	795,043
Basic and diluted loss per share | (per share)		SFr (1.36)	$ (1.36)	SFr (2.28)	$ (2.28)	SFr (14.46)	$ (14.46)
[1]	The basic and diluted loss per share for the year ended December 31, 2018 is revised to reflect the reverse-split ratio of 10 to 1 following the Merger on March 13, 2018 and the reverse-split ratio of 20 to 1 following the “reverse share split” on May 1, 2019.

Commitments and contingencies_2

Commitments and contingencies (Details)	12 Months Ended
	Dec. 31, 2020USD ($)	Dec. 31, 2019CHF (SFr)	Dec. 31, 2018USD ($)
Disclosure of commitments and contingent liabilities [text block] [Abstract]
Office lease expenses	$ 50,260	SFr 49,314	$ 118,337

Commitments and contingencies_3

Commitments and contingencies (Details) - Schedule of future minimum lease payments under non-cancellable operating leases - CHF (SFr)	Dec. 31, 2020	Dec. 31, 2019
Commitments and contingencies (Details) - Schedule of future minimum lease payments under non-cancellable operating leases [Line Items]
Minimum finance lease payments payable	SFr 25,580	SFr 24,980
Within one year [Member]
Commitments and contingencies (Details) - Schedule of future minimum lease payments under non-cancellable operating leases [Line Items]
Minimum finance lease payments payable	25,580	24,980
Between one and five years [Member]
Commitments and contingencies (Details) - Schedule of future minimum lease payments under non-cancellable operating leases [Line Items]
Minimum finance lease payments payable

Related party transactions (Det

Related party transactions (Details)	12 Months Ended
	Dec. 31, 2020CHF (SFr)	Dec. 31, 2020USD ($)	Dec. 31, 2019CHF (SFr)	Dec. 31, 2019USD ($)	Dec. 31, 2018CHF (SFr)
Disclosure of related party [text block] [Abstract]
Fees paid	SFr 173,030		SFr 11,770
Fees payment for other services	3,025		28,611
Payroll charge	522,237		934,179		SFr 1,403,250
Fees amount	163,476		170,755		287,384
Share based payments	261,988		159,235		264,881
Pension amount		$ 26,870		$ 42,560	55,278
Stock option amount	SFr 769,101		SFr 271,999		SFr 703,235

Related party transactions (D_2

Related party transactions (Details) - Schedule of related party transaction - CHF (SFr)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Related party transactions (Details) - Schedule of related party transaction [Line Items]
Short term benefits	SFr 570,623	SFr 888,660	SFr 1,203,128
Post-employee benefits years	26,870	42,560	55,278
Share-based payment charge	261,988	159,235	264,881
Total	859,481	1,090,455	1,523,287
Executive Management [Member]
Related party transactions (Details) - Schedule of related party transaction [Line Items]
Short term benefits	407,147	717,905	1,002,707
Post-employee benefits years	26,870	42,560	55,278
Share-based payment charge	204,840	109,912	204,224
Total	638,857	870,377	1,262,209
Board of Directors [Member]
Related party transactions (Details) - Schedule of related party transaction [Line Items]
Short term benefits	163,476	170,755	200,421
Post-employee benefits years
Share-based payment charge	57,148	49,323	60,657
Total	SFr 220,624	SFr 220,078	SFr 261,078

Loan and Warrant (Details)

Loan and Warrant (Details)	Jan. 31, 2019$ / sharesshares	Jul. 19, 2016CHF (SFr)	Dec. 31, 2020CHF (SFr)	Dec. 31, 2019CHF (SFr)	Dec. 31, 2020$ / shares	Sep. 07, 2020
Loan and Warrant (Details) [Line Items]
Drawn on term loan facility			SFr 523,920
Debt instrument, maturity date		Jan. 2, 2020
Interest rate per annum						8.00%
Exercise price of warrants | $ / shares					$ 240
Secured term loan facility [Member]
Loan and Warrant (Details) [Line Items]
Term loan facility		SFr 20,000,000
Drawn on term loan facility		SFr 12,500,000
Interest rate per annum		9.55%
Receivables related, description			The loan was secured by a pledge of the shares of Auris Medical AG owned by the Company, all intercompany receivables owed to the Company by its Swiss subsidiaries and a security assignment of the Company’s bank accounts. On April 5, 2018 the Company entered into an agreement with Hercules whereby the terms of the Hercules Loan and Security Agreement were amended to eliminate the $5 million liquidity covenant in exchange for a repayment of $5 million principal amount outstanding under the Hercules Loan and Security Agreement. The loan was initially recognized at transaction value with deductions of the fair value of the warrant at transaction date and directly attributable transactions costs. Subsequent to initial recognition, the loan was measured at amortized cost using the effective interest method.
Number of common shares exercisable through warrants | shares	783
Exercise price of warrants | $ / shares	$ 788
Fair value revaluation gain related, description				the fair value of the warrant amounted to CHF 0.00. There was no revaluation gain or loss for the twelve months ended December, 2020 (2019: revaluation gain of CHF 3,804). Since its initial recognition as of July 19, 2016, the fair value decreased by CHF 408,180 resulting in a revaluation gain in the corresponding amount (fair value as of July 19, 2016: CHF 408,180).

Loan (Details)

Loan (Details) - CHF (SFr)	Sep. 07, 2020	Sep. 07, 2020	Dec. 31, 2020
Disclosure Of Loanstext Block [Abstract]
Convertible loan agreement amount		SFr 1,500,000
Interest rate	8.00%	8.00%
Accrued interest	130.00%
Pricing of conversion description			The pricing of a conversion into our common shares is at the lower of 150% of the share price at close of the disbursement date ($1.35 fixed on September 8, 2020) and 95% of the average price of our common share at close of the 5 trading dates preceding the date of the conversion notice. However, the conversion price shall not be less than the higher of the par value and the backward-looking 3-month floor price of 75% of the average closing price of our common shares. The pricing of a conversion into Altamira shares is at the lower of CHF 3.00 and the issue price of a qualified financing round, meaning that a third-party investor will hold at least 10% of Altamira shares after completion of such financing round. The convertible loan agreement further contains a limitation on the conversion rights in the sense that they may not result in an ownership interest of more than 9.99% in the Company or 49.99% in Altamira. By December 31, 2020, an amount of CHF 895,455 has been converted into 737,000 common shares of the Company (at a conversion price of $1.35).
Expected volatility, share options granted			90.90%
Unconverted outstanding loan amounted			SFr 473,920
Outstanding loan units amount			310,439
Embedded derivatives			2,248,257
Effective interest			SFr 127,418

Loan (Details) - Schedule of lo

Loan (Details) - Schedule of loan - CHF (SFr)	Dec. 31, 2020	Dec. 31, 2019
Loan (Details) - Schedule of loan [Line Items]
Total	SFr 523,920
Loan guaranteed by Swiss government (COVID-19) [Member]
Loan (Details) - Schedule of loan [Line Items]
Total	50,000
Convertible Loan Agreement [Member]
Loan (Details) - Schedule of loan [Line Items]
Total	SFr 473,920

Loan (Details) - Schedule of co

Loan (Details) - Schedule of convertible loan agreement - CHF (SFr)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Schedule of convertible loan agreement [Abstract]
Gross proceeds at disbursement date	SFr 1,500,000
Embedded derivative, separated	(230,974)
Transaction costs allocated to host	(22,495)
Carrying amount at initial recognition	1,246,531
Converted principal amount	(895,455)
Accrued interest at 8%	31,920
Amortization transaction costs and derivative	90,923
Total	SFr 473,920

Warrants from Public Offering (

Warrants from Public Offering (Details)	1 Months Ended					12 Months Ended
	Jul. 17, 2018CHF (SFr)SFr / sharesshares	Jan. 30, 2018$ / sharesshares	Feb. 28, 2017CHF (SFr)	Feb. 21, 2017CHF (SFr)shares	Feb. 21, 2017USD ($)$ / sharesshares	Dec. 31, 2020CHF (SFr)shares	Dec. 31, 2019CHF (SFr)shares	Dec. 31, 2019USD ($)shares	Dec. 31, 2018CHF (SFr)	Dec. 31, 2020$ / sharesshares
Warrants from Public Offering (Details) [Line Items]
Number of shares issued							4,125,949	4,125,949		11,417,159
Transaction costs recognized in profit or loss (in Francs) | SFr						SFr 219,615			SFr 520,125
Description of fair value of warrants				The underwriter was granted a 30-day option to purchase up to 1,500,000 (pre-merger) additional common shares and/or 1,500,000 (pre-merger) additional warrants. On February 15, 2017, the underwriter partially exercised its 30-day option to purchase additional common shares and/or warrants in the amount of 1,350,000 (pre-merger) warrants.	The underwriter was granted a 30-day option to purchase up to 1,500,000 (pre-merger) additional common shares and/or 1,500,000 (pre-merger) additional warrants. On February 15, 2017, the underwriter partially exercised its 30-day option to purchase additional common shares and/or warrants in the amount of 1,350,000 (pre-merger) warrants.
Exercise price | $ / shares										$ 240
Warrants issued						39,725
Revaluation of derivative description						The revaluation loss of the derivative for the twelve months ended December 31, 2020 amounted to CHF 1,965 (2019: revaluation gain of CHF 285,298). Since its initial recognition on January 30, 2018, the fair value of the warrants has decreased by CHF 2,477,429 resulting in a gain in the corresponding amount (fair value as of January 30, 2018: CHF 2,483,747).
Warrant [Member]
Warrants from Public Offering (Details) [Line Items]
Number of shares issued					10,000,000
Conversion ratio		0.6		0.70	0.70
Common shares issued				7,945,000	7,945,000
Exercise price | $ / shares		$ 100			$ 1.20					$ 100
Gross proceeds (in Francs) | SFr			SFr 5,091,817
Warrants issued		62,499				37,501
Fair value of warrants (in Francs) | SFr						SFr 0
Issued capital [member]
Warrants from Public Offering (Details) [Line Items]
Gross proceeds (in Francs) | SFr			4,906,488
Series B Warrants [member]
Warrants from Public Offering (Details) [Line Items]
Number of shares issued	224,358
Conversion ratio	0.25
Common shares issued							143,221	143,221
Exercise price | SFr / shares	SFr 7.80
Fair value of warrants (in Francs) | SFr	SFr 4,353					SFr 6,318
Revaluation of derivative description						no Series B warrants were outstanding and subject to revaluation on December 31, 2020. As of December 31, 2019, the number of Series B warrants outstanding subject to revaluation were 34,535 and the fair value amounted to CHF 0.00. Accordingly, there was no revaluation gain or loss on these warrants for the year ended December 31, 2020 (2019: revaluation gain of CHF 215,572).
Warrants exercised for aggregate amount (in Dollars) | $								$ 1,117,125
Number of warrants exercised							143,221	143,221
Fair value of warrant exercised (in Francs) | SFr							SFr 3,005,348
Fair value of warrants description							Since its initial recognition on July 17, 2018 the fair value of the warrants has increased by CHF 2,433,099, resulting in a loss in the corresponding amounts (fair value as of July 17, 2018: CHF 572,249). On June 18, 2020, the Series B warrants expired without further warrants being exercised.	Since its initial recognition on July 17, 2018 the fair value of the warrants has increased by CHF 2,433,099, resulting in a loss in the corresponding amounts (fair value as of July 17, 2018: CHF 572,249). On June 18, 2020, the Series B warrants expired without further warrants being exercised.
Warrants outstanding subject to revaluation							34,535	34,535
Series A Warrants [member]
Warrants from Public Offering (Details) [Line Items]
Number of shares issued	314,102
Conversion ratio	0.35
Common shares issued	897,435						145,226	145,226
Warrants exercised for aggregate amount (in Dollars) | $								$ 1,132,762
Public offering [Member]
Warrants from Public Offering (Details) [Line Items]
Number of shares issued					10,000,000
Conversion ratio				0.40	0.40
Net proceeds after underwriting discounts				SFr 9.1	$ 9,100,000
Share issue related cost (in Francs) | SFr				903,919
Transaction costs recognized in equity (in Francs) | SFr				397,685
Transaction costs recognized in profit or loss (in Francs) | SFr				SFr 506,234
Gross proceeds (in Francs) | SFr			SFr 9,998,305

Events after the balance shee_2

Events after the balance sheet date (Details) - USD ($) $ in Thousands	Mar. 04, 2021	Jan. 15, 2021	Dec. 31, 2020
Events after the balance sheet date (Details) [Line Items]
Additional common shares			$ 3,200
Non-adjusting events after reporting period [Member]
Events after the balance sheet date (Details) [Line Items]
Common shares issued (in Shares)	516,814	1,758,618
Non-adjusting events after reporting period [Member]
Events after the balance sheet date (Details) [Line Items]
Additional common shares		$ 8,000
Gross proceeds		3,250
Non-adjusting events after reporting period [Member] | AGP Sales Agreement [Member]
Events after the balance sheet date (Details) [Line Items]
Additional common shares		$ 25,000